CEN Biotech (CENBF) 10-Q 19 Nov 21 2021 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Sep. 30, 2021	Nov. 19, 2021
Document Information [Line Items]
Entity Central Index Key	0001653821
Entity Registrant Name	CEN BIOTECH INC
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2021
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2021
Document Transition Report	false
Entity File Number	000-55557
Entity Incorporation, State or Country Code	A6
Entity Address, Address Line One	300-3295 Quality Way
Entity Address, City or Town	Windsor
Entity Address, Country	CA
Entity Address, Postal Zip Code	N8T 3R9
City Area Code	519
Local Phone Number	419-4958
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		52,812,013

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Current assets
Cash and cash equivalents	$ 213,805	$ 1,908
Accounts receivable	164,407	0
Prepaid expenses and other assets	18,694	0
Loan receivable from Emergence Global Enterprises Inc. - related party	0	17,901
Total current assets	396,906	19,809
Other assets
Operating lease right-of-use assets	150,323	0
Other receivable	0	113,999
Note receivable - CEN Biotech Ukraine LLC - related party	44,859	44,859
Advances to CEN Biotech Ukraine LLC - related party	1,299,328	1,179,328
Property and equipment, net	103,825	0
Intangible assets, net	5,278,867	4,956,147
Goodwill	1,127,857	0
Total assets	8,401,965	6,314,142
Current liabilities
Accounts payable	283,694	190,716
Accounts payable – related parties	61,651	8,347
Loans payable	1,986,670	527,379
Loans payable – related parties	2,701,452	1,363,354
Convertible notes payable	749,526	6,652,448
Convertible notes payable- related parties	1,036,434	2,558,681
Accrued interest	1,323,520	1,125,034
Accrued interest – related parties	1,804,448	1,615,880
Operating lease liabilities	94,439	22,895
Accrued expenses	829,266	641,023
Total current liabilities	10,871,100	14,705,757
Operating lease liabilities, less current portion	224,336	142,102
Patent acquisition liability	354,900	1,380,000
Convertible notes, less current portion	0	78,000
CEBA loan payable	31,396	0
Total liabilities	11,481,732	16,305,859
Shareholders’ deficit
Common stock; unlimited authorized shares; 47,786,013 and 27,557,363 issued and outstanding as of September 30, 2021 and December 31, 2020, respectively. No par value.	0	0
Additional paid-in capital	40,860,279	17,068,810
Accumulated deficit	(43,895,667)	(27,060,527)
Accumulated other comprehensive loss	(44,379)	0
Total shareholders’ deficit	(3,079,767)	(9,991,717)
Total liabilities and shareholders’ deficit	$ 8,401,965	$ 6,314,142

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals) - $ / shares $ / shares in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Common stock, par value (in dollars per share)	$ 0	$ 0
Common stock, shares issued (in shares)	47,786,013	27,557,363
Common stock, shares outstanding (in shares)	47,786,013	27,557,363
Common stock, authorized	Unlimited	Unlimited

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Other Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Revenue	$ 272,166	$ 0	$ 272,166	$ 0
Operating expenses
Consulting fees and subcontractors	308,782	136,000	1,205,782	298,077
Consulting fees – related parties	53,914	31,200	131,914	93,600
Stock based compensation	75,750	196,650	15,077,072	589,950
General and administrative	478,696	268,487	1,110,791	871,907
Loss on operating lease right-of-use asset - lease abandonment	0	146,795	0	146,795
Loss on lease termination	0	53,692	0	53,692
Loss on disposal of property and equipment	0	135,600	0	135,600
Total operating expenses	917,142	968,424	17,525,559	2,189,621
Loss from operations	(644,976)	(968,424)	(17,253,393)	(2,189,621)
Other income (expense)
Interest expense	(71,567)	(813,984)	(365,170)	(2,409,129)
Interest expense – related parties	(101,845)	(107,033)	(338,495)	(318,543)
Interest income	87	1,553	481	5,465
Governmental assistance income	116,610	0	116,610	0
Change in fair value of patent acquisition liability	(52,900)	0	1,025,100	0
Foreign exchange (loss) gain	35,651	(38,288)	(20,273)	25,659
Other income (expense), net	(73,964)	(957,752)	418,253	(2,696,548)
Net loss	(718,940)	(1,926,176)	(16,835,140)	(4,886,169)
Other comprehensive loss - Foreign currency translation	(44,379)	0	(44,379)	0
Comprehensive loss	$ (763,319)	$ (1,926,176)	$ (16,879,519)	$ (4,886,169)
Net loss per share:
Basic and diluted (in dollars per share)	$ (0.02)	$ (0.07)	$ (0.44)	$ (0.18)
Weighted average number of shares outstanding
Basic and diluted (in shares)	47,341,589	27,334,031	38,625,095	27,172,985

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Shareholders' Deficit (Unaudited) - USD ($)	Conversion of Convertible Notes into Common Stock [Member]Common Stock [Member]	Conversion of Convertible Notes into Common Stock [Member]Additional Paid-in Capital [Member]	Conversion of Convertible Notes into Common Stock [Member]Retained Earnings [Member]	Conversion of Convertible Notes into Common Stock [Member]AOCI Attributable to Parent [Member]	Conversion of Convertible Notes into Common Stock [Member]	Conversion of Related Party Convertible Notes into Common stock [Member]Common Stock [Member]	Conversion of Related Party Convertible Notes into Common stock [Member]Additional Paid-in Capital [Member]	Conversion of Related Party Convertible Notes into Common stock [Member]Retained Earnings [Member]	Conversion of Related Party Convertible Notes into Common stock [Member]AOCI Attributable to Parent [Member]	Conversion of Related Party Convertible Notes into Common stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Total
Balances (in shares) at Dec. 31, 2019											26,953,363
Balances at Dec. 31, 2019											$ 0	$ 15,775,010	$ (41,310,172)	$ 0	$ (25,535,162)
Stock-based compensation (in shares)											0
Stock-based compensation											$ 0	589,950	0	0	589,950
Issuance of common stock – interest shares (in shares)											135,000
Issuance of common stock – interest shares											$ 0	97,200	0	0	97,200
Issuance of common stock - consulting (in shares)											387,500
Issuance of common stock - consulting											$ 0	279,000	0	0	279,000
Issuance of common stock – lease termination settlement (in shares)											36,500
Stock Issued During Period, Value, Issued for Settlement of Lease Termination											$ 0	50,700	0	0	50,700
Net loss											$ 0	0	(4,886,169)	0	(4,886,169)
Net income (loss)															(4,886,169)
Issuance of common stock - settlement of accrued liability (in shares)											0
Issuance of common stock - settlement of accrued liability											$ 0	58,500	0	0	58,500
Issuance of common stock – lease termination settlement											$ 0	50,700	0	0	50,700
Balances (in shares) at Sep. 30, 2020											27,512,363
Balances at Sep. 30, 2020											$ 0	16,850,360	(46,196,341)	0	(29,345,981)
Balances (in shares) at Jun. 30, 2020											27,268,363
Balances at Jun. 30, 2020											$ 0	16,453,610	(44,270,165)	0	(27,816,555)
Stock-based compensation (in shares)											0
Stock-based compensation											$ 0	196,650	0	0	196,650
Issuance of common stock – interest shares (in shares)											45,000
Issuance of common stock – interest shares											$ 0	32,400	0	0	32,400
Issuance of common stock - consulting (in shares)											162,500
Issuance of common stock - consulting											$ 0	117,000	0	0	117,000
Issuance of common stock – lease termination settlement (in shares)											36,500
Stock Issued During Period, Value, Issued for Settlement of Lease Termination											$ 0	50,700	0	0	50,700
Net loss											0	0	(1,926,176)	0	(1,926,176)
Net income (loss)															(1,926,176)
Issuance of common stock – lease termination settlement											$ 0	50,700	0	0	50,700
Balances (in shares) at Sep. 30, 2020											27,512,363
Balances at Sep. 30, 2020											$ 0	16,850,360	(46,196,341)	0	(29,345,981)
Balances (in shares) at Dec. 31, 2020											27,557,363
Balances at Dec. 31, 2020											$ 0	17,068,810	(27,060,527)	0	(9,991,717)
Stock-based compensation (in shares)											11,409,291
Stock-based compensation											$ 0	15,077,072	0	0	15,077,072
Issuance of common stock – interest shares (in shares)											129,000
Issuance of common stock – interest shares											$ 0	127,023	0	0	127,023
Issuance of common stock - consulting (in shares)											1,150,000
Issuance of common stock - consulting											$ 0	1,172,000	0	0	1,172,000
Net loss															(16,835,140)
Issuance of common stock - acquisition of Clear Com Media, Inc. (in shares)											4,000,000
Issuance of common stock - acquisition of Clear Com Media, Inc.											$ 0	2,120,000	0	0	2,120,000
Issuance of common stock – upon conversion of convertible notes (in shares)	3,395,133					42,500
Issuance of common stock – upon conversion of convertible notes	$ 0	$ 5,023,785	$ 0	$ 0	$ 5,023,785	$ 0	$ 68,000	$ 0	$ 0	$ 68,000
Net income (loss)											$ 0	0	(16,835,140)	(44,379)	(16,879,519)
Issuance of common stock - settlement of accrued liability (in shares)											8,369
Issuance of common stock - settlement of accrued liability											$ 0	13,390	0	0	13,390
Beneficial conversion feature on convertible notes issued											$ 0	111,306	0	0	111,306
Issuance of common stock – upon conversion of convertible notes	0	5,023,785	0	0	5,023,785	0	68,000	0	0	68,000
Issuance of common stock – upon conversion of convertible notes – related parties	$ 0	5,023,785	0	0	$ 5,023,785	$ 0	$ 68,000	$ 0	$ 0	$ 68,000
Issuance of common stock – settlement of accrued interest (in shares)					94,357						94,357
Issuance of common stock – settlement of accrued interest											$ 0	78,893	0	0	78,893
Balances (in shares) at Sep. 30, 2021											47,786,013
Balances at Sep. 30, 2021											$ 0	40,860,279	(43,895,667)	(44,379)	(3,079,767)
Balances (in shares) at Jun. 30, 2021											43,142,060
Balances at Jun. 30, 2021											$ 0	38,197,932	(43,176,727)	0	(4,978,795)
Stock-based compensation (in shares)											0
Stock-based compensation											$ 0	75,750	0	0	75,750
Issuance of common stock – interest shares (in shares)											39,000
Issuance of common stock – interest shares											$ 0	23,673	0	0	23,673
Issuance of common stock - consulting (in shares)											500,000
Issuance of common stock - consulting											$ 0	275,000	0	0	275,000
Net loss															(718,940)
Issuance of common stock - acquisition of Clear Com Media, Inc. (in shares)											4,000,000
Issuance of common stock - acquisition of Clear Com Media, Inc.											$ 0	2,120,000	0	0	2,120,000
Issuance of common stock – upon conversion of convertible notes (in shares)	104,953
Issuance of common stock – upon conversion of convertible notes	$ 0	167,924	0	0	$ 167,924
Net income (loss)											$ 0	0	(718,940)	(44,379)	(763,319)
Issuance of common stock – upon conversion of convertible notes	0	167,924	0	0	167,924
Issuance of common stock – upon conversion of convertible notes – related parties	$ 0	$ 167,924	$ 0	$ 0	$ 167,924
Balances (in shares) at Sep. 30, 2021											47,786,013
Balances at Sep. 30, 2021											$ 0	$ 40,860,279	$ (43,895,667)	$ (44,379)	$ (3,079,767)

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Cash flows from operating activities
Net loss	$ (16,835,140)	$ (4,886,169)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation	10,968	10,724
Amortization	342,959	318,609
Amortization of debt discount	84,526	0
Lease expense	9,650	5,377
Loss on disposal of property and equipment	0	135,600
Loss on operating lease right-of-use asset - lease abandonment	0	146,795
Loss on operating lease right-of-use asset - lease termination settlement	0	2,992
Stock-based compensation – employees	15,077,072	589,950
Stock-based compensation – non-employees	1,172,000	279,000
Shares issued related to lease termination settlement	0	50,700
Non-cash services expense	0	19,000
Shares issued for interest	127,023	97,200
Change in fair value of patent acquisition liability	(1,025,100)	0
Foreign exchange loss (gain)	20,273	(25,659)
Changes in operating assets and liabilities which provided (used) cash, net of amounts acquired in 2021 business acquisition
Accounts receivable	34,267	0
Prepaid expenses and other assets	32,287	0
Income taxes	61,236	0
Other receivable	89,370	144,244
Accounts payable	(3,568)	20,439
Accounts payable – related parties	(786)	8,347
Accrued interest – related and non-related parties	445,912	2,589,945
Accrued expenses	101,019	93,600
Net cash used in operating activities	(256,032)	(399,306)
Cash flows provided by (used in) investing activities
Cash acquired upon acquisition of Clear Com Media, Inc.	259,470	0
Advances to CEN Biotech Ukraine LLC	(120,000)	(105,000)
Capitalized software development	(53,751)	0
Purchases of equipment	(18,988)	0
Proceeds from sale of equipment	0	1,801
Net cash provided by (used in) investing activities	66,731	(103,199)
Cash flows provided by financing activities
Repayment of loans payable - related parties	(50,000)	0
Issuance of convertible notes	412,830	499,000
Issuance of convertible notes – related parties	48,000	0
Net cash provided by financing activities	410,830	499,000
Effect of exchange rate changes on cash	(9,632)	0
Net increase in cash and cash equivalents	211,897	(3,505)
Cash and cash equivalents, beginning of period	1,908	3,757
Cash and cash equivalents, end of period	213,805	252
Supplemental cash flows disclosures
Cash paid for interest	25,821	41,527
Non-cash transactions - investing and financing activities
Issuance of common stock - settlement of interest	78,893	0
Issuance of common stock - settlement of accrued liability	13,390	58,500
Issuance of note payable for services	0	19,000
Clear Com Media, Inc [Member]
Acquisition of Clear Com Media, Inc.:
Fair value of assets acquired	2,581,329	0
Issuance of common stock - acquisition of Clear Com Media, Inc.	2,120,000	0
Liabilities assumed	461,329	0
Convertible Debt [Member]
Non-cash transactions - investing and financing activities
Debt Instrument, Convertible, Beneficial Conversion Feature	111,306	0
Conversion of Convertible Notes into Common Stock [Member]
Non-cash transactions - investing and financing activities
Issuance of common stock – upon conversion of convertible notes	5,023,785	0
Conversion of Related Party Convertible Notes into Common stock [Member]
Non-cash transactions - investing and financing activities
Issuance of common stock – upon conversion of convertible notes	$ 68,000	$ 0

Note 1 - Basis of Presentation

Note 1 - Basis of Presentation and Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]	NOTE 1 BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES The accompanying unaudited interim condensed consolidated financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information, and with the rules and regulations of the United States Securities and Exchange Commission (the “SEC”) set forth in Article 8 X. not not December 31, 2020 The Company's critical accounting policies are disclosed in its Annual Report on Form 10 December 31, 2020. 10 July 9, 2021. not Consolidation CEN Biotech, Inc.’s (“CEN”) consolidated financial statements include the accounts of CEN, Clear Com Media, Inc. (“CCM”), and Eastern Starr (collectively, the “Company”). CCM is a Windsor, Ontario based digital marketing, and e-commerce company. CCM’s purpose is to develop, market and sell various digital products. Additionally, CCM will provide in-house IT support functions for CEN’s activities. Eastern Starr’s purpose is to facilitate future growth opportunities in the LED lighting sector. All material intercompany transactions are eliminated in consolidation. Use of Estimates and Assumptions The accompanying condensed consolidated financial statements include certain estimates and assumptions which affect the reported amounts of assets and disclosure of contingent assets and liabilities at the date of the financial statements (including intangible assets and goodwill), and the reported amounts of revenues and expenses during the reporting period, including stock-based compensation. Accordingly, actual results may Loss per Share Net loss per common share is computed pursuant to Accounting Standards Codification (ASC) 260 10 45. three nine September 30, 2021 2020, not Revenue from Contracts with Customers The Company has agreements with third no not not not The Company derived approximately 99% of its revenue from one customer during the three nine September 30, 2021. July 9, 2021. Cash and Cash Equivalents For purposes of the balance sheet and statement of cash flows, the Company considers all highly liquid instruments with a maturity of three Accounts Receivable Accounts receivable are customer obligations due under normal trade terms generally requiring payment within 30 60 no not Property and Equipment Property and equipment are recorded at cost. Major improvements and renewals are capitalized while ordinary maintenance and repairs are expensed. Management reviews these assets for impairment whenever events or changes in circumstances indicate the related carrying amount may not Intangible Assets Product Technology, Trade Names, and Customer Relationships 3 may not Capitalized Software Development Costs third not September 30, 2021. Goodwill Goodwill arising from business combinations represents the excess of purchase consideration exchanged by the Company over the estimated fair value of the net assets of acquired businesses. The Company evaluates goodwill for impairment on an annual basis. In completing this evaluation, the Company considers the profitability of Clear Com Media, Inc. and compares its best estimate of future cash flows with the net carrying value of goodwill. Income Taxes Deferred income tax assets and liabilities are computed annually for differences between the financial statement and income tax bases of assets and liabilities that will result in taxable or deductible amounts in the future, based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. Income tax expense is the tax payable or refundable for the year plus or minus the change during the year in deferred tax assets and liabilities. Tax Credits The Company’s research and development activities in Canada may Foreign Currency Foreign denominated monetary assets and liabilities of CEN are translated at the rate of exchange prevailing at the consolidated balance sheet date. Other assets and liabilities denominated in foreign currencies are translated at the exchange rates prevailing when the assets were acquired or the liabilities incurred. Sales and expenses are translated at the average exchange rate over the reporting period. Transaction gains or losses are included in the determination of net income. The functional currency of CCM is the Canadian dollar. The accounts of CCM were translated to United States dollars equivalents at exchange rates as follows: balance sheet assets and liabilities were converted at period-end rates, equity at historical rates, and income statement accounts at average rates for the period. The resulting translation gain or loss is reflected in other comprehensive loss and accumulated other comprehensive loss in the condensed consolidated statements of operations and comprehensive loss and consolidated statements of shareholders’ deficit, respectively. Recent Developments On April 20, 2021, may no July 9, 2021 ( At Closing, the Company increased the number of members on its Board of Directors (the “Board”) by one At Closing, the Company entered into an employment agreement (the “Employment Agreement”) with Mr. Lehoux. Pursuant to the Employment Agreement, during the term of the Employment Agreement, the Company agreed to employ, and Mr. Lehoux agreed to accept employment with the Company as the Company’s Chief Technology Officer. Pursuant to the Employment Agreement, the Company agreed to pay Mr. Lehoux an annual base salary of $31,200. On October 7, 2021 ( Pursuant to the Transaction Documents, the Company agreed to complete the purchase, acquisition and acceptance from the Sellers of the Purchased Assets, which include all of the Sellers’ right, title, and interest in and to United States patent number U.S. 8,723,425 U.S. Patent Application No. Application Filing Date Status U.S. Patent No. Issue Date Subject Matter 13/525,703 06/18/2012 Issued U.S. Patent 8,723,425 05/13/2014 Light Emitting Diode Driver Circuit The Sellers cooperated with the Company to perfect the sale and assignment of the Patent and Property, including through execution of the Patent Assignment and recordation of the same with the U.S. Patent Office, on October 7, 2021. August 2016. As consideration for the sale, assignment and transfer of the Purchased Assets (the “Tesla Digital Transaction”), on the Closing Date the Company agreed to pay to the Sellers (i) 5,000,000 shares of the Company’s Common Stock, at no 1517 1525 135 Pursuant to notice given to its current transfer agent on Closing Date, the Company has authorized and instructed transfer agent to reserve the Shares of the Company for issuance upon the written request of any of the Sellers in accordance with the terms therein and following written confirmation by the Company. The Transaction Documents are the definitive agreements between the Company and Sellers, following a Sale Purchase Agreement for the sale of certain assets, properties and rights dated August 31, 2016, March 29, 2018, September 30, 2018, April 3, 2019 March 16, 2020. Recently Adopted Accounting Pronouncements No nine September 30, 2021. Recent Accounting Pronouncements Not In August 2020, 2020 06 December 15, 2023. January 1, 2022.

Note 2 - Going Concern Uncertai

Note 2 - Going Concern Uncertainty / Management Plans	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Substantial Doubt about Going Concern [Text Block]	NOTE 2 GOING CONCERN UNCERTAINTY / MANAGEMENT PLANS The accompanying condensed consolidated financial statements have been prepared in contemplating continuation of the Company as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. However, a substantial doubt has been raised with regard to the ability of the Company to continue as a going concern. The Company has incurred significant operating losses and negative cash flows from operations since inception. The Company had an accumulated deficit of $43,895,667 at September 30, 2021 no not July 9, 2021 not 7, 8, 9, 10. 19 no not The Company’s cash position may not

Note 3 - Acquisition of Clear C

Note 3 - Acquisition of Clear Com Media, Inc	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Business Combination Disclosure [Text Block]	NOTE 3 ACQUISTION OF CLEAR COM MEDIA, INC. As described in Note 1, July 9, 2021. The merger will be accounted for as a business combination using the acquisition method of accounting under the provisions of Accounting Standards Codification (ASC) 805, 805 805 may not one may See Note 21 The aggregate consideration for the acquisition of CCM was 4,000,000 restricted shares of CEN common stock, which were valued at $2,120,000 based upon the closing stock price on July 9, 2021. Cash $ 259,470 Accounts receivable 202,527 Property and equipment 97,911 Other assets 244,540 Identifiable intangibles 625,170 Current financial liabilities (321,251 ) Other long-term liabilities (140,078 ) Total identifiable net assets 968,289 Goodwill 1,151,711 Net assets acquired $ 2,120,000 Identified intangible assets acquired includes trade names, customer relationships, and product technology whose fair value of $625,170 is based on a provisional amount, pending receipt of additional appraisals. These assets are expected be amortized over useful-lives ranging from 3 to 7 years and will reviewed for impairment at least annually or more frequently if indicators of impairment exist. Amounts recognized as goodwill are expected to be fully deductible for Canadian income tax purposes. Costs related to the acquisition, which include legal, accounting, and valuation fees, in the amount of approximately $80,000 have been charged directly to operations and are included in general and administrative expenses in the 2021 Supplemental proforma financial information The unaudited financial information in the table below summarizes the combined results of operations of CEN and CCM on a pro forma basis, as though the companies had been combined as of the January 1, 2020. not January 1, 2020. 4,000,000 January 1, 2020 The pro forma financial information for the three nine September 30, 2021 July 9, 2021, July 1, 2021 July 8, 2021 six June 30, 2021. three nine September 30, 2020 three nine September 30, 2020. The following table summarizes the pro forma financial information: Three-Months Ended Nine-Months Ended September 30, 2021 September 30, 2020 September 30, 2021 September 30, 2020 Revenue $ 320,637 $ 310,210 $ 951,284 $ 906,875 Operating expenses 943,803 1,249,508 18,412,579 3,032,209 Loss from operations (623,166 ) (939,298 ) (17,461,295 ) (2,125,334 ) Other (expense) income (73,670 ) (866,513 ) 944,926 (2,492,515 ) Net income (loss) $ (696,836 ) $ (1,825,511 ) $ (16,516,369 ) $ (4,617,849 ) Net Loss Per Share Basic and Diluted $ (0.01 ) $ (0.06 ) $ (0.40 ) $ (0.15 ) Weighted Average Number of Shares Outstanding Basic and Diluted 49,412,822 31,334,031 41,394,326 31,172,985

Note 4 - Property, Plant and Im

Note 4 - Property, Plant and Improvements, Net	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Property, Plant and Equipment Disclosure [Text Block]	NOTE 4 Property and equipment, net consists of the following as of: September 30, 2021 Computers and equipment $ 62,574 Furniture and fixtures 32,900 Leasehold improvements 19,208 114,682 Less: accumulated depreciation and amortization 10,857 Net property and equipment $ 103,825 Effective August 1, 2020, 20 third third 13 three nine September 30, 2020. no July 9, 2021. Depreciation expense was $10,968 and $1,532 for the three September 30, 2021 2020, nine September 30, 2021 2020,

Note 5 - Advances to CEN Biotec

Note 5 - Advances to CEN Biotech Ukraine and Loan Receivable from Emergence Global	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Advances to Related Party [Text Block]	NOTE 5 ADVANCES TO CEN BIOTECH UKRAINE AND LOAN RECEIVABLE FROM EMERGENCE GLOBAL At December 31, 2020, 16 December 31, 2021. not April 19, 2021. April 12, 2021. 402 2002, May 6, 2021, May 6, 2021. not At September 30, 2021 December 31, 2020, 16 Bahige (Bill) Chaaban, Chief Executive Officer and member of our Board of Directors, and Usamakh Saadikh, a member of our Board of Directors, each directly own 25.5% of CEN Ukraine respectively. The remaining 49% of CEN Ukraine is owned by XN Pharma, which is an entity jointly owned by Bahige (Bill) Chaaban and Usamakh Saadikh. Bahige (Bill) Chaaban and Usamakh Saadikh do not not

Note 6 - Intangible Assets

Note 6 - Intangible Assets	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Intangible Assets Disclosure [Text Block]	NOTE 6 INTANGIBLE ASSETS Lighting Patent On September 12, 2016, August 31, 2016, The patent remained in the name of Tesla Digital, Inc. until full settlement of the terms of the agreement. In the interim, pursuant to an updated agreement executed on April 15, 2019 not In March 2018, September 30, 2021 December 31, 2020, Subsequently, on October 7, 2021, five 7. The Company intends to explore using the patented LED Lighting Technology across manufacturing operations and licensing opportunities across multiple industries such as horticultural, automotive, industrial and commercial lighting. The assets acquired, other than the patent, included certain machinery and raw materials, which were old and non-functioning and accordingly, had no Intangible assets consist of the following at: September 30, 2021 December 31, 2020 Lighting patent $ 6,797,000 $ 6,797,000 Product technology 345,356 - Customer relationships 219,772 - Capitalized software development costs 53,215 - Trade names 47,094 - Total identifiable intangible assets 7,462,437 6,797,000 Less: Accumulated amortization 2,183,570 1,840,853 Net $ 5,278,867 $ 4,956,147 As of September 30, 2021 December 31, 2020, not 2031, 2032. July 9, 2021 2023, 2024, 2025 2026, 2028. 3

Note 7 - Loans Payable

Note 7 - Loans Payable	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Short-term Debt [Text Block]	NOTE 7 LOANS PAYABLE Loans payable consist of the following at: September 30, 2021 December 31, 2020 Loan payable to Global Holdings International, LLC, which bears interest at 15% June 30, 2016 $ 75,000 $ 75,000 Mortgage payable in default to ARG & Pals, Inc., for the original amount of CAD 385,000 22% September 21, 2021 302,186 302,379 Loan payable to an individual, issued January 17, 2018 with a 30-day maturity, bearing share interest of 2,000 July 16, 2021 50,000 50,000 Loan payable in default to an individual, issued April 13, 2018, with a 30-day maturity, bearing share interest of 4,000 December 16, 2021 100,000 100,000 Loans payable in default to multiple private investors bearing an interest at rates of up to 12% June 2018 May 2021 592,395 - Loans payable to a private investor for the original amount of CAD 1,104,713 7% 867,089 - Total loans payable (all current) $ 1,986,670 $ 527,379 During each of the three September 30, 2021 2020, three September 30, 2021 2020, During each of the nine September 30, 2021 2020, nine September 30, 2021 2020, During the three nine September 30, 2021, no

Note 8 - Loans Payable- Related

Note 8 - Loans Payable- Related Party	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Loans Payable to Related Party [Text Block]	NOTE 8 LOANS PAYABLE- RELATED PARTY Loans payable - related party consists of the following at: September 30, 2021 December 31, 2020 Loan payable in default due to the spouse of Bill Chaaban, CEO of CEN, which bears an interest at 12% August 17, 2020 $ 1,388,122 $ - Loans payable in default to the spouse of Bill Chaaban, CEO of CEN, for the original amounts of CAD 48,630 $198,660 10% December 31, 2018 236,830 236,854 Loans payable in default to a former director of Creative, former parent company, bear interest at 10% December 31, 2018 601,500 601,500 Loan payable in default to R&D Labs Canada, Inc., whose president is Bill Chaaban, also the CEO of CEN, bearing interest at 8% October 2, 2019 300,000 300,000 Loan payable to the spouse of Joseph Byrne, a 5% 4,000 December 16, 2021 100,000 100,000 Loan payable to Alex Tarrabain, CFO and a Director of CEN, issued January 17, 2018 with a 30-day maturity, bearing share interest of 3,000 December 16, 2021 75,000 75,000 Loan payable to Joseph Byrne, a 5% 2,000 - 50,000 Total loans payable - related party (all current) $ 2,701,452 $ 1,363,354 Attributable related party accrued interest was $644,360 and $568,969 as of September 30, 2021 December 31, 2020, three September 30, 2021 2020, nine September 30, 2021 2020, During the three September 30, 2021 2020, three September 30, 2021 2020, During the nine September 30, 2021 2020, nine September 30, 2021 2020,

Note 9 - Convertible Notes

Note 9 - Convertible Notes	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Long-term Debt [Text Block]	NOTE 9 CONVERTIBLE NOTES Convertible notes payable consists of the following at: September 30, 2021 December 31, 2020 Convertible notes payable in default to multiple private investors, including certain notes in default, bearing interest at 5% 457,517 May 2018 October 2021 $ 726,472 $ 5,862,807 Convertible notes payable with beneficial conversion features at original issuance to multiple private investors, bearing interest at 5% 94,298 June 2022 35,000 - Convertible note payable, due on demand, for the original amount of CAD 1,104,713 7% 335,833 - 867,641 Total convertible notes payable 761,472 6,730,448 Less unamortized debt discount 11,946 - Total convertible notes payable, net of unamortized debt discount 749,526 6,730,448 Less current portion 749,526 6,652,448 Convertible notes payable, less current portion $ - $ 78,000 The Company issues convertible notes as a method to raise operating capital. These notes convert to a fixed number of shares specified in the convertible note, at the option of the note holder. Certain of these notes are considered to contain a beneficial conversion feature if in-the-money at the time of issuance. The Company has determined the value associated with the beneficial conversion feature in connection with the notes issued during nine September 30, 2021 2021 three September 30, 2021 three nine September 30, 2020. These notes may During the three September 30, 2021, nine September 30, 2021, no three nine September 30, 2020. During the nine September 30, 2021, no three September 30, 2021 2020 nine September 30, 2020. As of November 19, 2021,

Note 10 - Convertible Notes Pay

Note 10 - Convertible Notes Payable - Related Parties	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Long-term Convertible Notes Related Party [Text Block]	NOTE 10 CONVERTIBLE NOTES PAYABLE - RELATED PARTIES Convertible notes payable - related parties consists of the following at: September 30, 2021 December 31, 2020 Convertible notes in default due to Harold Aubrey de Lavenu, a Vice President and Director of CEN, bearing interest at 5% 548,980 March 31, 2019 $ 878,368 $ 878,368 Convertible notes in default due to Joseph Byrne, former CEO, and current President and member of the board of CEN, bearing interest at 12% 76,123 August 17, 2020 121,796 224,191 Convertible notes with beneficial conversion features due to the parents of Jeffery Thomas, a Director of CEN, bearing interest at 5% 94,488 May 24, 2022 48,000 - Convertible note in default due to the spouse of Bill Chaaban, CEO of CEN, which bears an interest at 12% 867,576 August 17, 2020 - 1,388,122 Convertible note in default due to Alex Tarrabain, CFO and a Director of CEN, bearing interest at 5% 30,000 - 48,000 Convertible note due to Darren Ferris, brother of Ameen Ferris, a Vice President and a Director of CEN, bearing interest at 5% 12,500 - 20,000 Total convertible notes payable – related parties 1,048,164 2,558,681 Less unamortized debt discount 11,730 - Total convertible notes payable - related parties (all current) $ 1,036,434 $ 2,558,681 Attributable related party accrued interest was $1,160,088 and $1,046,911 as of September 30, 2021 December 31, 2020, three September 30, 2021 2020, nine September 30, 2021 2020, The Company issues convertible notes to related parties as a method to raise operating capital. These notes convert to a fixed number of shares specified in the convertible note, at the option of the note holder. Certain of these notes are considered to contain a beneficial conversion feature if in-the-money at the time of issuance. The Company has determined the value associated with the beneficial conversion feature in connection with the notes issued to related parties during the nine September 30, 2021 2021 three September 30, 2021 three nine September 30, 2020. These notes may During the nine September 30, 2021, As of November 19, 2021,

Note 11 - CEBA Loan Payable

Note 11 - CEBA Loan Payable	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Loan Payable , Disclosure [Text Block]	NOTE 11 CEBA LOAN PAYABLE The Canada Emergency Business Account (“CEBA”) loan payable of $31,396 (CAD 40,000) as of September 30, 2021 December 2022 December 2025.

Note 12 - Governmental Assistan

Note 12 - Governmental Assistance	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Governmental Assistance Disclosure [Text Block]	NOTE 12 GOVERNMENTAL ASSISTANCE The Canadian government enacted the Canada Emergency Wage Subsidy (“CEWS”) and Canada Emergency Rent Subsidy (“CERS”) in 2020 19 three nine September 30, 2021

Note 13 - Leases

Note 13 - Leases	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Lessee, Operating Leases [Text Block]	NOTE 13 LEASES The Company currently leases certain facilities and equipment under noncancelable operating lease agreements that expire at various dates through 2024. The Company also leased office space in Windsor, Ontario from RN Holdings Ltd. Under the lease agreement effective October 1, 2017, September 2022, August 1, 2020, no August 1, 2020. August 1, 2020 November 19, 2021, not September 30, 2021 The operating lease liability as of September 30, 2021 December 31, 2020 three September 30, 2021 2020, nine September 30, 2021 2020, The following is a schedule of future annual minimum rental payments required under operating leases with initial or remaining noncancelable lease terms in excess of one 12 September 30, 2021: Amount 2022 $ 110,969 2023 89,879 2024 75,522 2025 31,930 2026 31,930 Thereafter 31,930 Total lease payments $ 372,159 Less imputed interest 53,384 Present value of lease liability $ 318,775

Note 14 - Income Taxes

Note 14 - Income Taxes	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Income Tax Disclosure [Text Block]	NOTE 14 INCOME TAXES A reconciliation of the effective tax rate of the income tax benefit and the statutory income tax rates applied to the loss before income taxes is as follows for the three nine September 30: 2021 2020 Income tax benefit at Canadian statutory rate 26.5 % 26.5 % Valuation allowance (26.5 %) (26.5 %) Effective income tax rate 0 % 0 % As of September 30, 2021, may 20 2034. may not not September 30, 2021 December 31, 2020: September 30, 2021 December 31, 2020 Deferred tax asset - net operating losses $ 7,700,000 $ 3,400,000 Deferred tax asset valuation allowance (7,700,000 ) (3,400,000 ) Net deferred tax asset $ - $ - The valuation allowance increased $100,000 and $700,000 for the three September 30, 2021 2020, nine September 30, 2021 2020, Company management analyzes its income tax filing positions in Canadian federal and provincial jurisdictions where it is required to file income tax returns, for all open tax years in these jurisdictions, to identify potential uncertain tax positions. As of September 30, 2021, no no no 2017.

Note 15 - Shareholders' Deficit

Note 15 - Shareholders' Deficit / Stock Activity	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	NOTE 15 SHAREHOLDERS DEFICIT / STOCK ACTIVITY The Company is authorized to issue an unlimited number of common shares and an unlimited number of special voting shares. Common shares have no stated par value. As of September 30, 2021,

Note 16 - Related Party Transac

Note 16 - Related Party Transactions	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	NOTE 16 RELATED PARTY TRANSACTIONS The Company has received loans from several related parties, as described above in Notes 8 10. A loan totaling $17,901 was made to Emergence Global as of December 31, 2020. July 2017 November 13, 2019. May 6, 2021, 5. There are advances of $1,299,328 and $1,179,328 to CEN Biotech Ukraine as of September 30, 2021 December 31, 2020, 5. December 3, 2017, December 14, 2017, not November 19, 2021, not not On July 12, 2017, During the three September 30, 2021 2020, nine September 30, 2021 2020, September 30, 2021 December 31, 2020, During 2017, 10 2017 2026. No September 30, 2021, Jamaal Shaban (“Lessor”), cousin of Bill Chaaban, leased 20 10.4 two January 2017 five third October 2019. August 1, 2020, August 1, 2020 three nine September 30, 2020,

Note 17 - Stock Based Compensat

Note 17 - Stock Based Compensation	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Share-based Payment Arrangement [Text Block]	NOTE 17 STOCK BASED COMPENSATION Adoption of Equity Compensation Plan On November 29, 2017, 2017 On April 2, 2021, 2021 “2021 2021 Equity Compensation Grants On November 30, 2017, one 36 November 2020. 36 November 2020. On October 1, 2019, On April 17, 2020, three On August 27, 2020 September 25, 2020, two On April 2, 2021, 12 On July 13, 2021, two Employment Agreements On November 30, 2017, four ● Under the Employment Agreement with Bahige (Bill) Chaaban, then President of the Company, Mr. Chaaban agreed to receive compensation in the form of a base annual salary of $31,200 and a grant of 8,750,000 shares of restricted stock of the Company, of which 7,400,000 vested immediately and the remaining vested ratably each month over the next 36 November 2020. ● Under the Employment Agreement with Joseph Byrne, former Chief Executive Officer of the Company, Mr. Byrne agreed to receive compensation in the form of a base annual salary of $31,200 and a grant of 1,250,000 shares of restricted stock of the Company, of which 325,000 vested immediately and the remaining vesting ratably each month over the next 36 November 2020. November 13, 2019, April 2, 2020, not April 19, 2021, ● Under the Employment Agreement with Richard Boswell, Senior Executive Vice President and then Chief Financial Officer of the Company, Mr. Boswell agreed to receive compensation in the form of a base annual salary of $31,200 and a grant of 4,500,000 shares of restricted stock of the Company, of which 4,140,000 vested immediately and the remaining vested ratably each month over the next 36 November 2020. ● Under the Employment Agreement with Brian Payne, Vice President of the Company, Mr. Payne agreed to receive compensation in the form of a base annual salary of $31,200 36 November 2020. On May 16, 2019, one one May 21, 2019: ● Under the Employment Agreement with Alex Tarrabain, Chief Financial Officer and as one 36 May 2022. On April 2, 2021, On April 2, 2021, 2021 On April 2, 2021, 2021 On April 2, 2021, 2021 On April 2, 2021, 2021 On April 2, 2021, 2021 On April 2, 2021 June 25, 2021, 2021 Restricted Stock Awards Restricted stock awards relate to common shares that are subject to applicable securities laws and regulations as set forth in the RSAs and other equity compensation grants. The total grant-date fair value of the restricted shares noted in the employment agreements and equity compensation grants sections above was $29,035,063 and $13,013,241 as of September 30, 2021 December 31, 2020, three nine September 30, 2021, three nine September 30, 2020, April 5, 2021 April 5, 2021, With the exception of immediately vesting portions of awards, shares typically vest pro-rata over the requisite service period, which is generally three During the three September 30, 2021 2020, nine September 30, 2021 2020, three September 30, 2021 2020, nine September 30, 2021 2020, Compensation expense recognized in connection with the restricted stock awards was $75,750 and $196,650 for the three September 30, 2021 2020, nine September 30, 2021 2020, three September 30, 2021 2020, nine September 30, 2021 2020, Non-vested restricted stock award activity for the nine September 30, 2021 2020 Number of Shares Weighted- Average Grant Date Fair Value per Share Weighted- Average Remaining Contractual Term (Years) Non-vested at January 1, 2020 2,025,000 $ 0.76 1.54 Granted 387,500 0.72 - Vested (1,737,500 ) 0.71 - Forfeited - - - Non-vested at September 30, 2020 675,000 $ 0.91 1.36 Non-vested at January 1, 2021 425,000 $ 1.01 1.50 Granted 12,559,291 1.28 - Vested (12,784,291 ) 1.27 - Forfeited - - - Non-vested at September 30, 2021 200,000 $ 1.01 0.75 The fair value of the restricted stock grants was based on the valuation of a third April 5, 2021. April 5, 2021, September 30, 2021, May 2022.

Note 18 - Net Loss Per Share

Note 18 - Net Loss Per Share	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Earnings Per Share [Text Block]	NOTE 18 NET LOSS PER SHARE During periods when there is a net loss, all potentially dilutive shares are anti-dilutive and are excluded from the calculation of diluted net loss per share. Based on the Company’s application of the as-converted and treasury stock methods, all common stock equivalents were excluded from the computation of diluted earnings per share due to net losses as of September 30, 2021 2020. three nine September 30, 2021 2020 Three-months Ended Nine-months Ended September 30, September 30, 2021 2020 2021 2020 Convertible debt 1,271,406 5,733,735 1,163,866 5,425,999

Note 19 - Contingency

Note 19 - Contingency	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	NOTE 19 CONTINGENCY In connection with the distribution by Creative of CEN’s common stock on February 29, 2016 10 May 4, 2016 5 not

Note 20 - Fair Value Disclosure

Note 20 - Fair Value Disclosures	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Fair Value Disclosures [Text Block]	NOTE 20 FAIR VALUE DISCLOSURES Fair value is the price that would be received from the sale of an asset or paid to transfer a liability assuming an orderly transaction in the most advantageous market at the measurement date. U.S. GAAP establishes a hierarchical disclosure framework that prioritizes and ranks the level of observability of inputs used in measuring fair value. The fair value of the Company’s financial instruments are as follows at: Fair Value Measured at Reporting Date Using Carrying Amount Level 1 Level 2 Level 3 Fair Value At September 30, 2021: Cash and cash equivalents $ 213,805 $ - $ 213,805 $ - $ 213,805 Note receivable – CEN Biotech Ukraine, LLC – related party $ 44,859 $ - $ - $ 44,859 $ 44,859 Advances to CEN Biotech Ukraine, LLC - related party $ 1,299,328 $ - $ - $ 1,299,328 $ 1,299,328 Loans payable $ 1,986,670 $ - $ - $ 1,986,670 $ 1,986,670 Loans payable – related parties $ 2,701,452 $ - $ - $ - $ - Patent acquisition liability $ 354,900 $ 354,900 $ - $ - $ 354,900 Convertible notes payable $ 749,526 $ - $ - $ 1,962,985 $ 1,962,985 Convertible notes payable – related parties $ 1,036,434 $ - $ - $ - $ - CEBA loan payable $ 31,396 $ - $ - $ 31,396 $ 31,396 Carrying Amount Level 1 Level 2 Level 3 Fair Value At December 31, 2020: Cash and cash equivalents $ 1,908 $ - $ 1,908 $ - $ 1,908 Other receivables $ 113,999 $ - $ - $ 113,999 $ 113,999 Note receivable – CEN Biotech Ukraine, LLC – related party $ 44,859 $ - $ - $ 44,859 $ 44,859 Advances to Emergence Global - related party $ 17,901 $ - $ - $ 17,901 $ 17,901 Advances to CEN Biotech Ukraine, LLC - related party $ 1,179,328 $ - $ - $ 1,179,328 $ 1,179,328 Loans payable $ 527,379 $ - $ - $ 527,379 $ 527,379 Loans payable – related parties $ 1,363,354 $ - $ - $ - $ - Patent acquisition liability $ 1,380,000 $ - $ - $ 1,380,000 $ 1,380,000 Convertible notes payable $ 6,730,448 $ - $ - $ 7,766,663 $ 7,766,663 Convertible notes payable – related parties $ 2,558,681 $ - $ - $ - $ - The fair values of other receivables (including related accrued interest), note receivable - CEN Biotech Ukraine, LLC, and advances to Emergence Global and CEN Biotech Ukraine, LLC approximate carrying value due to the terms of the instruments. The fair value of the loans payable approximates carrying value due to the terms of such instruments and applicable interest rates. The fair value of convertible notes payable is based on the par value plus accrued interest through the date of reporting due to the terms of such instruments and interest rates. It is not The fair value of the patent acquisition liability is based upon the fair value of the common stock, which was obtained from a 3 rd April 5, 2021. April 5, 2021, 3 1

Note 21 - Segment Information

Note 21 - Segment Information	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Segment Reporting Disclosure [Text Block]	NOTE 21 SEGMENT INFORMATION As described in Note 2, July 9, 2021. Segment information: Three-months Ended September 30, 2021 2020 Growth Digital Growth Digital Revenue $ - $ 272,166 $ - $ - Operating loss (570,311 ) (74,665 ) (968,424 ) - Depreciation expense - 10,968 1,532 - Amortization expense 106,203 24,350 106,203 - Interest income - 87 1,553 - Interest expense 173,412 - 921,017 - Capital expenditures - 18,988 - - Nine-months Ended September 30, 2021 2020 Growth Digital Growth Digital Revenue $ - $ 272,166 $ - $ - Operating loss (17,178,728 ) (74,665 ) (2,189,621 ) - Depreciation expense - 10,968 10,724 - Amortization expense 318,609 24,350 318,609 - Interest income 394 87 5,465 - Interest expense 703,665 - 2,727,672 - Capital expenditures - 18,988 - - Segment assets to total assets: September 30, 2021 December 31, 2020 Growth $ 5,989,211 $ 6,314,142 Digital 2,412,754 - Total assets $ 8,401,965 $ 6,314,142

Note 22 - Subsequent Events

Note 22 - Subsequent Events	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Subsequent Events [Text Block]	NOTE 22 SUBSEQUENT EVENTS From October 1, 2021 November 19, 2021, one

Significant Accounting Policies

Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2021
Accounting Policies [Abstract]
Consolidation, Policy [Policy Text Block]	Consolidation CEN Biotech, Inc.’s (“CEN”) consolidated financial statements include the accounts of CEN, Clear Com Media, Inc. (“CCM”), and Eastern Starr (collectively, the “Company”). CCM is a Windsor, Ontario based digital marketing, and e-commerce company. CCM’s purpose is to develop, market and sell various digital products. Additionally, CCM will provide in-house IT support functions for CEN’s activities. Eastern Starr’s purpose is to facilitate future growth opportunities in the LED lighting sector. All material intercompany transactions are eliminated in consolidation.
Use of Estimates, Policy [Policy Text Block]	Use of Estimates and Assumptions The accompanying condensed consolidated financial statements include certain estimates and assumptions which affect the reported amounts of assets and disclosure of contingent assets and liabilities at the date of the financial statements (including intangible assets and goodwill), and the reported amounts of revenues and expenses during the reporting period, including stock-based compensation. Accordingly, actual results may
Earnings Per Share, Policy [Policy Text Block]	Loss per Share Net loss per common share is computed pursuant to Accounting Standards Codification (ASC) 260 10 45. three nine September 30, 2021 2020, not
Revenue from Contract with Customer [Policy Text Block]	Revenue from Contracts with Customers The Company has agreements with third no not not not The Company derived approximately 99% of its revenue from one customer during the three nine September 30, 2021. July 9, 2021.
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and Cash Equivalents For purposes of the balance sheet and statement of cash flows, the Company considers all highly liquid instruments with a maturity of three
Accounts Receivable [Policy Text Block]	Accounts Receivable Accounts receivable are customer obligations due under normal trade terms generally requiring payment within 30 60 no not
Property, Plant and Equipment, Policy [Policy Text Block]	Property and Equipment Property and equipment are recorded at cost. Major improvements and renewals are capitalized while ordinary maintenance and repairs are expensed. Management reviews these assets for impairment whenever events or changes in circumstances indicate the related carrying amount may not
Intangible Assets, Finite-Lived, Policy [Policy Text Block]	Intangible Assets Product Technology, Trade Names, and Customer Relationships 3 may not Capitalized Software Development Costs third not September 30, 2021.
Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]	Goodwill Goodwill arising from business combinations represents the excess of purchase consideration exchanged by the Company over the estimated fair value of the net assets of acquired businesses. The Company evaluates goodwill for impairment on an annual basis. In completing this evaluation, the Company considers the profitability of Clear Com Media, Inc. and compares its best estimate of future cash flows with the net carrying value of goodwill.
Income Tax, Policy [Policy Text Block]	Income Taxes Deferred income tax assets and liabilities are computed annually for differences between the financial statement and income tax bases of assets and liabilities that will result in taxable or deductible amounts in the future, based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. Income tax expense is the tax payable or refundable for the year plus or minus the change during the year in deferred tax assets and liabilities.
Tax Credits, Policy [Policy Text Block]	Tax Credits The Company’s research and development activities in Canada may
Foreign Currency Transactions and Translations Policy [Policy Text Block]	Foreign Currency Foreign denominated monetary assets and liabilities of CEN are translated at the rate of exchange prevailing at the consolidated balance sheet date. Other assets and liabilities denominated in foreign currencies are translated at the exchange rates prevailing when the assets were acquired or the liabilities incurred. Sales and expenses are translated at the average exchange rate over the reporting period. Transaction gains or losses are included in the determination of net income. The functional currency of CCM is the Canadian dollar. The accounts of CCM were translated to United States dollars equivalents at exchange rates as follows: balance sheet assets and liabilities were converted at period-end rates, equity at historical rates, and income statement accounts at average rates for the period. The resulting translation gain or loss is reflected in other comprehensive loss and accumulated other comprehensive loss in the condensed consolidated statements of operations and comprehensive loss and consolidated statements of shareholders’ deficit, respectively.
Recent Developments, Policy [Policy Text Block]	Recent Developments On April 20, 2021, may no July 9, 2021 ( At Closing, the Company increased the number of members on its Board of Directors (the “Board”) by one At Closing, the Company entered into an employment agreement (the “Employment Agreement”) with Mr. Lehoux. Pursuant to the Employment Agreement, during the term of the Employment Agreement, the Company agreed to employ, and Mr. Lehoux agreed to accept employment with the Company as the Company’s Chief Technology Officer. Pursuant to the Employment Agreement, the Company agreed to pay Mr. Lehoux an annual base salary of $31,200. On October 7, 2021 ( Pursuant to the Transaction Documents, the Company agreed to complete the purchase, acquisition and acceptance from the Sellers of the Purchased Assets, which include all of the Sellers’ right, title, and interest in and to United States patent number U.S. 8,723,425 U.S. Patent Application No. Application Filing Date Status U.S. Patent No. Issue Date Subject Matter 13/525,703 06/18/2012 Issued U.S. Patent 8,723,425 05/13/2014 Light Emitting Diode Driver Circuit The Sellers cooperated with the Company to perfect the sale and assignment of the Patent and Property, including through execution of the Patent Assignment and recordation of the same with the U.S. Patent Office, on October 7, 2021. August 2016. As consideration for the sale, assignment and transfer of the Purchased Assets (the “Tesla Digital Transaction”), on the Closing Date the Company agreed to pay to the Sellers (i) 5,000,000 shares of the Company’s Common Stock, at no 1517 1525 135 Pursuant to notice given to its current transfer agent on Closing Date, the Company has authorized and instructed transfer agent to reserve the Shares of the Company for issuance upon the written request of any of the Sellers in accordance with the terms therein and following written confirmation by the Company. The Transaction Documents are the definitive agreements between the Company and Sellers, following a Sale Purchase Agreement for the sale of certain assets, properties and rights dated August 31, 2016, March 29, 2018, September 30, 2018, April 3, 2019 March 16, 2020.
New Accounting Pronouncements, Policy [Policy Text Block]	Recently Adopted Accounting Pronouncements No nine September 30, 2021. Recent Accounting Pronouncements Not In August 2020, 2020 06 December 15, 2023. January 1, 2022.

Note 3 - Acquisition of Clear_2

Note 3 - Acquisition of Clear Com Media, Inc (Tables)	9 Months Ended
	Sep. 30, 2021
Notes Tables
Schedule of Business Acquisitions, by Acquisition [Table Text Block]	Cash $ 259,470 Accounts receivable 202,527 Property and equipment 97,911 Other assets 244,540 Identifiable intangibles 625,170 Current financial liabilities (321,251 ) Other long-term liabilities (140,078 ) Total identifiable net assets 968,289 Goodwill 1,151,711 Net assets acquired $ 2,120,000
Business Acquisition, Pro Forma Information [Table Text Block]	Three-Months Ended Nine-Months Ended September 30, 2021 September 30, 2020 September 30, 2021 September 30, 2020 Revenue $ 320,637 $ 310,210 $ 951,284 $ 906,875 Operating expenses 943,803 1,249,508 18,412,579 3,032,209 Loss from operations (623,166 ) (939,298 ) (17,461,295 ) (2,125,334 ) Other (expense) income (73,670 ) (866,513 ) 944,926 (2,492,515 ) Net income (loss) $ (696,836 ) $ (1,825,511 ) $ (16,516,369 ) $ (4,617,849 ) Net Loss Per Share Basic and Diluted $ (0.01 ) $ (0.06 ) $ (0.40 ) $ (0.15 ) Weighted Average Number of Shares Outstanding Basic and Diluted 49,412,822 31,334,031 41,394,326 31,172,985

Note 4 - Property, Plant and _2

Note 4 - Property, Plant and Improvements, Net (Tables)	9 Months Ended
	Sep. 30, 2021
Notes Tables
Property, Plant and Equipment [Table Text Block]	September 30, 2021 Computers and equipment $ 62,574 Furniture and fixtures 32,900 Leasehold improvements 19,208 114,682 Less: accumulated depreciation and amortization 10,857 Net property and equipment $ 103,825

Note 6 - Intangible Assets (Tab

Note 6 - Intangible Assets (Tables)	9 Months Ended
	Sep. 30, 2021
Notes Tables
Schedule of Finite-Lived Intangible Assets [Table Text Block]	September 30, 2021 December 31, 2020 Lighting patent $ 6,797,000 $ 6,797,000 Product technology 345,356 - Customer relationships 219,772 - Capitalized software development costs 53,215 - Trade names 47,094 - Total identifiable intangible assets 7,462,437 6,797,000 Less: Accumulated amortization 2,183,570 1,840,853 Net $ 5,278,867 $ 4,956,147

Note 7 - Loans Payable (Tables)

Note 7 - Loans Payable (Tables)	9 Months Ended
	Sep. 30, 2021
Notes Tables
Schedule of Short-term Debt [Table Text Block]	September 30, 2021 December 31, 2020 Loan payable to Global Holdings International, LLC, which bears interest at 15% June 30, 2016 $ 75,000 $ 75,000 Mortgage payable in default to ARG & Pals, Inc., for the original amount of CAD 385,000 22% September 21, 2021 302,186 302,379 Loan payable to an individual, issued January 17, 2018 with a 30-day maturity, bearing share interest of 2,000 July 16, 2021 50,000 50,000 Loan payable in default to an individual, issued April 13, 2018, with a 30-day maturity, bearing share interest of 4,000 December 16, 2021 100,000 100,000 Loans payable in default to multiple private investors bearing an interest at rates of up to 12% June 2018 May 2021 592,395 - Loans payable to a private investor for the original amount of CAD 1,104,713 7% 867,089 - Total loans payable (all current) $ 1,986,670 $ 527,379

Note 8 - Loans Payable- Relat_2

Note 8 - Loans Payable- Related Party (Tables)	9 Months Ended
	Sep. 30, 2021
Notes Tables
Schedule of Loans Payable to Related Party [Table Text Block]	September 30, 2021 December 31, 2020 Loan payable in default due to the spouse of Bill Chaaban, CEO of CEN, which bears an interest at 12% August 17, 2020 $ 1,388,122 $ - Loans payable in default to the spouse of Bill Chaaban, CEO of CEN, for the original amounts of CAD 48,630 $198,660 10% December 31, 2018 236,830 236,854 Loans payable in default to a former director of Creative, former parent company, bear interest at 10% December 31, 2018 601,500 601,500 Loan payable in default to R&D Labs Canada, Inc., whose president is Bill Chaaban, also the CEO of CEN, bearing interest at 8% October 2, 2019 300,000 300,000 Loan payable to the spouse of Joseph Byrne, a 5% 4,000 December 16, 2021 100,000 100,000 Loan payable to Alex Tarrabain, CFO and a Director of CEN, issued January 17, 2018 with a 30-day maturity, bearing share interest of 3,000 December 16, 2021 75,000 75,000 Loan payable to Joseph Byrne, a 5% 2,000 - 50,000 Total loans payable - related party (all current) $ 2,701,452 $ 1,363,354

Note 9 - Convertible Notes (Tab

Note 9 - Convertible Notes (Tables)	9 Months Ended
	Sep. 30, 2021
Notes Tables
Schedule of Long-term Debt Instruments [Table Text Block]	September 30, 2021 December 31, 2020 Convertible notes payable in default to multiple private investors, including certain notes in default, bearing interest at 5% 457,517 May 2018 October 2021 $ 726,472 $ 5,862,807 Convertible notes payable with beneficial conversion features at original issuance to multiple private investors, bearing interest at 5% 94,298 June 2022 35,000 - Convertible note payable, due on demand, for the original amount of CAD 1,104,713 7% 335,833 - 867,641 Total convertible notes payable 761,472 6,730,448 Less unamortized debt discount 11,946 - Total convertible notes payable, net of unamortized debt discount 749,526 6,730,448 Less current portion 749,526 6,652,448 Convertible notes payable, less current portion $ - $ 78,000

Note 10 - Convertible Notes P_2

Note 10 - Convertible Notes Payable - Related Parties (Tables)	9 Months Ended
	Sep. 30, 2021
Notes Tables
Schedule of Convertible Notes Payable to Related Party [Table Text Block]	September 30, 2021 December 31, 2020 Convertible notes in default due to Harold Aubrey de Lavenu, a Vice President and Director of CEN, bearing interest at 5% 548,980 March 31, 2019 $ 878,368 $ 878,368 Convertible notes in default due to Joseph Byrne, former CEO, and current President and member of the board of CEN, bearing interest at 12% 76,123 August 17, 2020 121,796 224,191 Convertible notes with beneficial conversion features due to the parents of Jeffery Thomas, a Director of CEN, bearing interest at 5% 94,488 May 24, 2022 48,000 - Convertible note in default due to the spouse of Bill Chaaban, CEO of CEN, which bears an interest at 12% 867,576 August 17, 2020 - 1,388,122 Convertible note in default due to Alex Tarrabain, CFO and a Director of CEN, bearing interest at 5% 30,000 - 48,000 Convertible note due to Darren Ferris, brother of Ameen Ferris, a Vice President and a Director of CEN, bearing interest at 5% 12,500 - 20,000 Total convertible notes payable – related parties 1,048,164 2,558,681 Less unamortized debt discount 11,730 - Total convertible notes payable - related parties (all current) $ 1,036,434 $ 2,558,681

Note 13 - Leases (Tables)

Note 13 - Leases (Tables)	9 Months Ended
	Sep. 30, 2021
Notes Tables
Lessee, Operating Lease, Liability, Maturity [Table Text Block]	Amount 2022 $ 110,969 2023 89,879 2024 75,522 2025 31,930 2026 31,930 Thereafter 31,930 Total lease payments $ 372,159 Less imputed interest 53,384 Present value of lease liability $ 318,775

Note 14 - Income Taxes (Tables)

Note 14 - Income Taxes (Tables)	9 Months Ended
	Sep. 30, 2021
Notes Tables
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	2021 2020 Income tax benefit at Canadian statutory rate 26.5 % 26.5 % Valuation allowance (26.5 %) (26.5 %) Effective income tax rate 0 % 0 %
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	September 30, 2021 December 31, 2020 Deferred tax asset - net operating losses $ 7,700,000 $ 3,400,000 Deferred tax asset valuation allowance (7,700,000 ) (3,400,000 ) Net deferred tax asset $ - $ -

Note 17 - Stock Based Compens_2

Note 17 - Stock Based Compensation (Tables)	9 Months Ended
	Sep. 30, 2021
Notes Tables
Nonvested Restricted Stock Shares Activity [Table Text Block]	Number of Shares Weighted- Average Grant Date Fair Value per Share Weighted- Average Remaining Contractual Term (Years) Non-vested at January 1, 2020 2,025,000 $ 0.76 1.54 Granted 387,500 0.72 - Vested (1,737,500 ) 0.71 - Forfeited - - - Non-vested at September 30, 2020 675,000 $ 0.91 1.36 Non-vested at January 1, 2021 425,000 $ 1.01 1.50 Granted 12,559,291 1.28 - Vested (12,784,291 ) 1.27 - Forfeited - - - Non-vested at September 30, 2021 200,000 $ 1.01 0.75

Note 18 - Net Loss Per Share (T

Note 18 - Net Loss Per Share (Tables)	9 Months Ended
	Sep. 30, 2021
Notes Tables
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	Three-months Ended Nine-months Ended September 30, September 30, 2021 2020 2021 2020 Convertible debt 1,271,406 5,733,735 1,163,866 5,425,999

Note 20 - Fair Value Disclosu_2

Note 20 - Fair Value Disclosures (Tables)	9 Months Ended
	Sep. 30, 2021
Notes Tables
Fair Value, by Balance Sheet Grouping [Table Text Block]	Fair Value Measured at Reporting Date Using Carrying Amount Level 1 Level 2 Level 3 Fair Value At September 30, 2021: Cash and cash equivalents $ 213,805 $ - $ 213,805 $ - $ 213,805 Note receivable – CEN Biotech Ukraine, LLC – related party $ 44,859 $ - $ - $ 44,859 $ 44,859 Advances to CEN Biotech Ukraine, LLC - related party $ 1,299,328 $ - $ - $ 1,299,328 $ 1,299,328 Loans payable $ 1,986,670 $ - $ - $ 1,986,670 $ 1,986,670 Loans payable – related parties $ 2,701,452 $ - $ - $ - $ - Patent acquisition liability $ 354,900 $ 354,900 $ - $ - $ 354,900 Convertible notes payable $ 749,526 $ - $ - $ 1,962,985 $ 1,962,985 Convertible notes payable – related parties $ 1,036,434 $ - $ - $ - $ - CEBA loan payable $ 31,396 $ - $ - $ 31,396 $ 31,396 Carrying Amount Level 1 Level 2 Level 3 Fair Value At December 31, 2020: Cash and cash equivalents $ 1,908 $ - $ 1,908 $ - $ 1,908 Other receivables $ 113,999 $ - $ - $ 113,999 $ 113,999 Note receivable – CEN Biotech Ukraine, LLC – related party $ 44,859 $ - $ - $ 44,859 $ 44,859 Advances to Emergence Global - related party $ 17,901 $ - $ - $ 17,901 $ 17,901 Advances to CEN Biotech Ukraine, LLC - related party $ 1,179,328 $ - $ - $ 1,179,328 $ 1,179,328 Loans payable $ 527,379 $ - $ - $ 527,379 $ 527,379 Loans payable – related parties $ 1,363,354 $ - $ - $ - $ - Patent acquisition liability $ 1,380,000 $ - $ - $ 1,380,000 $ 1,380,000 Convertible notes payable $ 6,730,448 $ - $ - $ 7,766,663 $ 7,766,663 Convertible notes payable – related parties $ 2,558,681 $ - $ - $ - $ -

Note 21 - Segment Information (

Note 21 - Segment Information (Tables)	9 Months Ended
	Sep. 30, 2021
Notes Tables
Schedule of Segment Reporting Information, by Segment [Table Text Block]	Three-months Ended September 30, 2021 2020 Growth Digital Growth Digital Revenue $ - $ 272,166 $ - $ - Operating loss (570,311 ) (74,665 ) (968,424 ) - Depreciation expense - 10,968 1,532 - Amortization expense 106,203 24,350 106,203 - Interest income - 87 1,553 - Interest expense 173,412 - 921,017 - Capital expenditures - 18,988 - - Nine-months Ended September 30, 2021 2020 Growth Digital Growth Digital Revenue $ - $ 272,166 $ - $ - Operating loss (17,178,728 ) (74,665 ) (2,189,621 ) - Depreciation expense - 10,968 10,724 - Amortization expense 318,609 24,350 318,609 - Interest income 394 87 5,465 - Interest expense 703,665 - 2,727,672 - Capital expenditures - 18,988 - -
Reconciliation of Assets from Segment to Consolidated [Table Text Block]	September 30, 2021 December 31, 2020 Growth $ 5,989,211 $ 6,314,142 Digital 2,412,754 - Total assets $ 8,401,965 $ 6,314,142

Note 1 - Basis of Presentatio_2

Note 1 - Basis of Presentation and Summary of Significant Accounting Policies (Details Textual) - USD ($) $ / shares in Thousands	Oct. 07, 2021	Jul. 09, 2021	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Jul. 08, 2021	Apr. 20, 2021	Dec. 31, 2020
Revenue from Contract with Customer, Excluding Assessed Tax, Total			$ 272,166	$ 0	$ 272,166	$ 0	$ 0
Common Stock, No Par Value (in dollars per share)			$ 0		$ 0				$ 0
Tesla Digital Transaction [Member] | Subsequent Event [Member]
Stock Issued During Period, Shares, Purchase of Assets (in shares)	5,000,000
Common Stock, No Par Value (in dollars per share)	$ 0
Chief Technology Officer [Member]
Annual Salary		$ 31,200
Clear Com Media, Inc [Member]
Share Exchange Agreement, Shares to Acquire (in shares)								10,000
Share Exchange Agreement, Shares to Issue (in shares)								4,000,000
Minimum [Member]
Property, Plant and Equipment, Useful Life (Year)					2 years
Finite-Lived Intangible Asset, Useful Life (Year)					3 years
Maximum [Member]
Property, Plant and Equipment, Useful Life (Year)					7 years
Finite-Lived Intangible Asset, Useful Life (Year)					7 years
Customer Concentration Risk [Member] | Revenue Benchmark [Member]
Number of Major Customers			1		1
Customer Concentration Risk [Member] | Revenue Benchmark [Member] | One Customer [Member]
Concentration Risk, Percentage			99.00%		99.00%

Note 2 - Going Concern Uncert_2

Note 2 - Going Concern Uncertainty / Management Plans (Details Textual) - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Retained Earnings (Accumulated Deficit), Ending Balance	$ (43,895,667)	$ (27,060,527)

Note 3 - Acquisition of Clear_3

Note 3 - Acquisition of Clear Com Media, Inc (Details Textual) - USD ($)	Jul. 09, 2021	Sep. 30, 2021	Sep. 30, 2021
Stock Issued During Period, Value, Acquisitions		$ 2,120,000	$ 2,120,000
Minimum [Member]
Finite-Lived Intangible Asset, Useful Life (Year)			3 years
Maximum [Member]
Finite-Lived Intangible Asset, Useful Life (Year)			7 years
Clear Com Media, Inc [Member]
Stock Issued During Period, Shares, Acquisitions (in shares)	4,000,000
Stock Issued During Period, Value, Acquisitions	$ 2,120,000
Finite-lived Intangible Assets Acquired	625,170
Clear Com Media, Inc [Member] | General and Administrative Expense [Member]
Business Combination, Acquisition Related Costs	$ 80,000
Clear Com Media, Inc [Member] | Minimum [Member]
Finite-Lived Intangible Asset, Useful Life (Year)	3 years
Clear Com Media, Inc [Member] | Maximum [Member]
Finite-Lived Intangible Asset, Useful Life (Year)	7 years

Note 3 - Acquisition of Clear_4

Note 3 - Acquisition of Clear Com Media, Inc - Estimate of Assets Acquired and Liabilities Assumed (Details) - USD ($)	Sep. 30, 2021	Jul. 09, 2021	Dec. 31, 2020
Goodwill	$ 1,127,857		$ 0
Clear Com Media, Inc [Member]
Cash		$ 259,470
Accounts receivable		202,527
Property and equipment		97,911
Other assets		244,540
Identifiable intangibles		625,170
Current financial liabilities		(321,251)
Other long-term liabilities		(140,078)
Total identifiable net assets		968,289
Goodwill		1,151,711
Net assets acquired		$ 2,120,000

Note 3 - Acquisition of Clear_5

Note 3 - Acquisition of Clear Com Media, Inc - Proforma Results of Operations (Details) - Clear Com Media, Inc [Member] - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Revenue	$ 320,637	$ 310,210	$ 951,284	$ 906,875
Operating expenses	943,803	1,249,508	18,412,579	3,032,209
Loss from operations	(623,166)	(939,298)	(17,461,295)	(2,125,334)
Other (expense) income	(73,670)	(866,513)	944,926	(2,492,515)
Net income (loss)	$ (696,836)	$ (1,825,511)	$ (16,516,369)	$ (4,617,849)
Basic and Diluted (in dollars per share)	$ (0.01)	$ (0.06)	$ (0.40)	$ (0.15)
Basic and Diluted (in shares)	49,412,822	31,334,031	41,394,326	31,172,985

Note 4 - Property, Plant and _3

Note 4 - Property, Plant and Improvements, Net (Details Textual) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Proceeds from Sale of Property, Plant, and Equipment, Total		$ 1,801	$ 0	$ 1,801
Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property	$ 0	(135,600)	0	(135,600)
Depreciation, Total	$ 10,968	$ 1,532	$ 10,968	$ 10,724

Note 4 - Property, Plant and _4

Note 4 - Property, Plant and Improvements, Net - Property, Plant and Improvement Placed in Service (Details) - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Property, plant and equipment, gross	$ 114,682
Less: accumulated depreciation and amortization	10,857
Net property and equipment	103,825	$ 0
Computer Equipment [Member]
Property, plant and equipment, gross	62,574
Furniture and Fixtures [Member]
Property, plant and equipment, gross	32,900
Leasehold Improvements [Member]
Property, plant and equipment, gross	$ 19,208

Note 5 - Advances to CEN Biot_2

Note 5 - Advances to CEN Biotech Ukraine and Loan Receivable from Emergence Global (Details Textual) - USD ($)	May 06, 2021	Sep. 30, 2021	Dec. 31, 2020	Dec. 02, 2017
Notes Receivable, Related Parties, Current		$ 0	$ 17,901
Emergence Global [Member]
Common Stock, Par or Stated Value Per Share (in dollars per share)	$ 0.82
Former CEO [Member]
Ownership Percentage			5.00%
CEN Biotech Ukraine [Member]
Notes Receivable, Related Parties, Current			$ 17,901
Due from Related Parties, Total		$ 1,299,328	1,179,328
Percentage of Related Party's Equity Interest Owned by Director				51.00%
CEN Biotech Ukraine [Member] | Usamakh Saadikh [Member]
Ownership Percentage		49.00%
Percentage of Related Party's Equity Interest Owned by Director		25.50%
Emergence Global [Member]
Notes Receivable, Related Parties, Current			$ 17,901
Notes Receivable, Original Amount Converted to Common Stock	$ 17,901
Notes Receivable, Converted Instrument, Shares Received as Payment (in shares)	21,830

Note 6 - Intangible Assets (Det

Note 6 - Intangible Assets (Details Textual) - USD ($)	Oct. 07, 2021	Jul. 09, 2021	Sep. 12, 2016	Sep. 30, 2018	Sep. 30, 2021	Dec. 31, 2020
Development of Acquired Technology, Annual Compensation for Specialist			$ 200,000
Contingent Consideration Classified as Equity, Fair Value Disclosure					$ 354,900	$ 1,380,000
Impairment of Real Estate					$ 0	$ 0
Minimum [Member]
Finite-Lived Intangible Asset, Useful Life (Year)					3 years
Minimum [Member] | Clear Com Media, Inc [Member]
Finite-Lived Intangible Asset, Useful Life (Year)		3 years
Maximum [Member]
Finite-Lived Intangible Asset, Useful Life (Year)					7 years
Maximum [Member] | Clear Com Media, Inc [Member]
Finite-Lived Intangible Asset, Useful Life (Year)		7 years
Lighting Patent [Member]
Finite-Lived Intangible Asset, Useful Life (Year)					16 years
Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year					$ 424,812
Finite-Lived Intangible Asset, Expected Amortization, Year Eleven					283,215
Finite-Lived Intangible Asset, Expected Amortization, Year Two					424,812
Finite-Lived Intangible Asset, Expected Amortization, Year Three					424,812
Finite-Lived Intangible Asset, Expected Amortization, Year Four					424,812
Finite-Lived Intangible Asset, Expected Amortization, Year Ten					424,812
Finite-Lived Intangible Asset, Expected Amortization, Year Nine					424,812
Finite-Lived Intangible Asset, Expected Amortization, Year Eight					424,812
Finite-Lived Intangible Asset, Expected Amortization, Year Seven					424,812
Finite-Lived Intangible Asset, Expected Amortization, Year Six					424,812
Finite-Lived Intangible Asset, Expected Amortization, Year Five					424,812
Finite-Lived Intangible Asset, Expected Amortization, Year One					$ 424,812
Intangibles, Excluding Lighting Patent [Member] | Clear Com Media, Inc [Member]
Finite-Lived Intangible Asset, Expected Amortization, Year Two		$ 96,400
Finite-Lived Intangible Asset, Expected Amortization, Year Three		88,600
Finite-Lived Intangible Asset, Expected Amortization, Year Four		80,700
Finite-Lived Intangible Asset, Expected Amortization, after Year Five		121,100
Finite-Lived Intangible Asset, Expected Amortization, Year Five		$ 80,700
Intangibles, Excluding Lighting Patent [Member] | Minimum [Member]
Finite-Lived Intangible Asset, Useful Life (Year)					3 years
Intangibles, Excluding Lighting Patent [Member] | Maximum [Member]
Finite-Lived Intangible Asset, Useful Life (Year)					15 years
Subsequent Event [Member] | Tesla Digital Transaction [Member]
Stock Issued During Period, Shares, Purchase of Assets (in shares)	5,000,000
Tesla Digital [Member]
Stock Issued During Period, Shares, Purchase of Assets (in shares)				1,000,000

Note 6 - Intangible Assets - In

Note 6 - Intangible Assets - Intangible Assets (Details) - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Finite-lived intangible assets, gross	$ 7,462,437	$ 6,797,000
Less: Accumulated amortization	2,183,570	1,840,853
Net	5,278,867	4,956,147
Lighting Patent [Member]
Finite-lived intangible assets, gross	6,797,000	6,797,000
Technology-Based Intangible Assets [Member]
Finite-lived intangible assets, gross	345,356	0
Customer Relationships [Member]
Finite-lived intangible assets, gross	219,772	0
Computer Software, Intangible Asset [Member]
Finite-lived intangible assets, gross	53,215	0
Trade Names [Member]
Finite-lived intangible assets, gross	$ 47,094	$ 0

Note 7 - Loans Payable (Details

Note 7 - Loans Payable (Details Textual)	3 Months Ended		9 Months Ended
	Sep. 30, 2021USD ($)shares	Sep. 30, 2020USD ($)shares	Sep. 30, 2021USD ($)shares	Sep. 30, 2020USD ($)shares
Stock Issued During Period, Value, New Issues	$ 23,673	$ 32,400	$ 127,023	$ 97,200
Short-term Loan Payable to Private Investors [Member]
Debt Instrument, Convertible, Beneficial Conversion Feature	$ 1,209,484		$ 1,459,484
Debt Instrument, Convertible, Number of Equity Instruments	549,830		677,955
Individual Lenders [Member]
Stock Issued During Period, Shares, New Issues (in shares) | shares	18,000	18,000	54,000	54,000
Stock Issued During Period, Value, New Issues	$ 10,926	$ 12,960	$ 52,266	$ 38,880

Note 7 - Loans Payable - Loans

Note 7 - Loans Payable - Loans Payable (Details) - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Loan payable	$ 1,986,670	$ 527,379
Short-term Loan Payable to Global Holdings International, LLC [Member]
Loan payable	75,000	75,000
Short-term Mortgage Payable to ARG & Pals, Inc. [Member]
Loan payable	302,186	302,379
Short-term Loan Payable to an Individual [Member]
Loan payable	50,000	50,000
Second Short-term Loan Payable to an Individual [Member]
Loan payable	100,000	100,000
Short-term Loan Payable to Multiple Investors [Member]
Loan payable	592,395	0
Short-term Loan Payable to Private Investors [Member]
Loan payable	$ 867,089	$ 0

Note 7 - Loans Payable - Loan_2

Note 7 - Loans Payable - Loans Payable (Details) (Parentheticals) - CAD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Short-term Loan Payable to Global Holdings International, LLC [Member]
Interest Rate	15.00%	15.00%
Maturity date	Jun. 30, 2016	Jun. 30, 2016
Short-term Mortgage Payable to ARG & Pals, Inc. [Member]
Interest Rate	22.00%	22.00%
Maturity date	Sep. 21, 2021	Sep. 21, 2021
Original Amount	$ 385,000	$ 385,000
Short-term Loan Payable to an Individual [Member]
Maturity date	Jul. 16, 2021	Jul. 16, 2021
Share Interest (in shares)	2,000	2,000
Second Short-term Loan Payable to an Individual [Member]
Maturity date	Dec. 16, 2021	Dec. 16, 2021
Share Interest (in shares)	4,000	4,000
Short-term Loan Payable to Multiple Investors [Member]
Interest Rate	12.00%	12.00%
Maturity Date, start	Jun. 1, 2018	Jun. 1, 2018
Maturity Date, end	May 31, 2021	May 31, 2021
Short-term Loan Payable to Private Investors [Member]
Interest Rate	7.00%
Original Amount	$ 1,104,713

Note 8 - Loans Payable- Relat_3

Note 8 - Loans Payable- Related Party (Details Textual) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020
Interest Expense, Related Party	$ 101,845	$ 107,033	$ 338,495	$ 318,543
Stock Issued During Period, Value, New Issues	$ 23,673	$ 32,400	$ 127,023	$ 97,200
Related Parties Lenders [Member]
Stock Issued During Period, Shares, New Issues (in shares)	21,000	27,000	75,000	81,000
Stock Issued During Period, Value, New Issues	$ 12,747	$ 19,440	$ 74,757	$ 58,320
Loans Payable to Related Party [Member]
Interest Payable, Related Party	644,360		644,360		$ 568,969
Interest Expense, Related Party	$ 39,927	$ 46,504	$ 155,452	$ 138,275

Note 8 - Loans Payable - Relate

Note 8 - Loans Payable - Related Party - Loans Payable to Related Parties (Details) - Loans Payable to Related Party [Member] - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Long-term Debt	$ 2,701,452	$ 1,363,354
Mr. Chaaban's Spouse [Member]
Long-term Debt	1,388,122	0
Bill Chaaban, President of Cen Biotech [Member]
Long-term Debt	236,830	236,854
Creative Edge [Member]
Long-term Debt	601,500	601,500
R&D Labs Canada, Inc [Member]
Long-term Debt	300,000	300,000
Spouse of Joseph Byrne, CEO of CEN Biotech [Member]
Long-term Debt	100,000	100,000
Director, Alex Tarrabain [Member]
Long-term Debt	75,000	75,000
Joseph Byrne [Member]
Long-term Debt	$ 0	$ 50,000

Note 8 - Loans Payable - Rela_2

Note 8 - Loans Payable - Related Party - Loans Payable to Related Parties (Details) (Parentheticals)	9 Months Ended	12 Months Ended
	Sep. 30, 2021USD ($)shares	Dec. 31, 2020USD ($)shares	Sep. 30, 2021CAD ($)shares	Dec. 31, 2020CAD ($)shares
Joseph Byrne [Member]
Related Party Interest	5.00%		5.00%
Loans Payable to Related Party [Member] | Mr. Chaaban's Spouse [Member]
Interest Rate	12.00%		12.00%
Maturity date	Aug. 17, 2020
Loans Payable to Related Party [Member] | Bill Chaaban, President of Cen Biotech [Member]
Interest Rate	10.00%	10.00%	10.00%	10.00%
Maturity date	Dec. 31, 2018	Dec. 31, 2018
Original Amount	$ 198,660	$ 198,660	$ 48,630	$ 48,630
Loans Payable to Related Party [Member] | Creative Edge [Member]
Interest Rate	10.00%	10.00%	10.00%	10.00%
Maturity date	Dec. 31, 2018	Dec. 31, 2018
Loans Payable to Related Party [Member] | R&D Labs Canada, Inc [Member]
Interest Rate	8.00%	8.00%	8.00%	8.00%
Maturity date	Oct. 2, 2019	Oct. 2, 2019
Loans Payable to Related Party [Member] | Spouse of Joseph Byrne, CEO of CEN Biotech [Member]
Maturity date	Dec. 16, 2021	Dec. 16, 2021
Share Interest (in shares)	4,000	4,000	4,000	4,000
Related Party Interest	5.00%	5.00%	5.00%	5.00%
Loans Payable to Related Party [Member] | Director, Alex Tarrabain [Member]
Maturity date	Dec. 16, 2021	Dec. 16, 2021
Share Interest (in shares)	3,000	3,000	3,000	3,000
Loans Payable to Related Party [Member] | Joseph Byrne [Member]
Share Interest (in shares)	2,000	2,000	2,000	2,000
Related Party Interest	5.00%	5.00%	5.00%	5.00%

Note 9 - Convertible Notes (Det

Note 9 - Convertible Notes (Details Textual)	Nov. 19, 2021USD ($)	Nov. 19, 2021USD ($)	Sep. 30, 2021USD ($)shares	Sep. 30, 2020USD ($)	Sep. 30, 2021USD ($)shares	Sep. 30, 2020USD ($)
Conversion of Convertible Notes into Common Stock [Member]
Debt Conversion, Original Debt, Amount			$ 167,924		$ 5,023,785
Debt Conversion, Converted Instrument, Shares Issued (in shares) | shares			104,953		3,395,133
Debt Conversion, Accrued Interest, Amount					$ 78,893
Stock Issued During Period, Shares, Settlement of Accrued Interest (in shares) | shares					94,357
Convertible Debt Payable to Non-related Party [Member]
Debt Instrument, Convertible, Beneficial Conversion Feature					$ 93,164
Convertible Debt [Member]
Debt Instrument, Convertible, Beneficial Conversion Feature			$ 0	$ 0	$ 111,306	$ 0
Debt Instrument, Convertible, Number of Equity Instruments					551,815
Convertible Debt [Member] | Subsequent Event [Member]
Debt Instrument, Convertible, Number of Equity Instruments	457,517	416,667
Debt Instrument, Debt Default, Amount	$ 726,472	$ 726,472

Note 9 - Convertible Notes - Co

Note 9 - Convertible Notes - Convertible Notes (Details) - Convertible Debt [Member] - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Long-term Debt, gross	$ 761,472	$ 6,730,448
Less unamortized debt discount	11,946	0
Long-term Debt	749,526	6,730,448
Less current portion	749,526	6,652,448
Convertible notes payable, less current portion	0	78,000
Convertible Notes 1[Member]
Long-term Debt, gross	726,472	5,862,807
Convertible Notes 2 [Member]
Long-term Debt, gross	35,000	0
Convertible Notes 3 [Member]
Long-term Debt, gross	$ 0	$ 867,641

Note 9 - Convertible Notes - _2

Note 9 - Convertible Notes - Convertible Notes (Details) (Parentheticals) - Convertible Debt [Member]	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020CAD ($)
Conversion Rights	551,815
Convertible Notes 1[Member]
Interest Rate	5.00%	5.00%
Conversion Rights	457,517	457,517
Maturity Date, start	May 1, 2018	May 1, 2018
Maturity Date, end	Oct. 31, 2021	Oct. 31, 2021
Convertible Notes 2 [Member]
Interest Rate	5.00%
Conversion Rights	94,298
Maturity date	Jun. 30, 2022
Convertible Notes 3 [Member]
Interest Rate		7.00%
Conversion Rights		335,883
Original Amount		$ 1,104,713

Note 10 - Convertible Notes P_3

Note 10 - Convertible Notes Payable - Related Parties (Details Textual)	Nov. 19, 2021USD ($)	Sep. 30, 2021USD ($)	Sep. 30, 2020USD ($)	Sep. 30, 2021USD ($)	Sep. 30, 2020USD ($)	Dec. 31, 2020USD ($)
Interest Expense, Related Party		$ 101,845	$ 107,033	$ 338,495	$ 318,543
Convertible Debt Payable to Related Party [Member]
Interest Payable, Related Party		1,160,088		1,160,088		$ 1,046,911
Interest Expense, Related Party		61,918	60,529	183,043	180,268
Debt Instrument, Convertible, Beneficial Conversion Feature		0	$ 9	18,142	$ 0
Long-term Debt, Total		1,036,434		$ 1,036,434		$ 2,558,681
Convertible Debt Payable to Related Party [Member] | Joseph Byrne [Member]
Debt Instrument, Convertible, Number of Equity Instruments				76,123		76,123
Convertible Debt Payable to Related Party Reclassified to Private Investor [Member]
Debt Instrument, Convertible, Number of Equity Instruments				719,591
Convertible Debt Payable to Related Party Reclassified to Private Investor [Member] | Subsequent Event [Member]
Debt Instrument, Convertible, Number of Equity Instruments	625,103
Debt Instrument, Debt Default, Amount	$ 1,000,164
Convertible Debt Payable to Related Party Reclassified to Private Investor [Member] | Joseph Byrne [Member]
Debt Instrument, Convertible, Number of Equity Instruments				63,997
Long-term Debt, Total		$ 102,395		$ 102,395

Note 10 - Convertible Notes P_4

Note 10 - Convertible Notes Payable - Related Parties - Convertible Notes Payable to Related Parties (Details) - Convertible Debt Payable to Related Party [Member] - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Long-term Debt, gross	$ 1,048,164	$ 2,558,681
Less unamortized debt discount	11,730	0
Long-term Debt	1,036,434	2,558,681
Bill Chaaban, President of Cen Biotech [Member]
Long-term Debt, gross	0	1,388,122
Director, Harold Aubrey de Lavenu [Member]
Long-term Debt, gross	878,368	878,368
Joseph Byrne [Member]
Long-term Debt, gross	121,796	224,191
Jeff Thomas [Member]
Long-term Debt, gross	48,000	0
Director, Alex Tarrabain [Member]
Long-term Debt, gross	0	48,000
Brother of Director Ameen Ferris [Member]
Long-term Debt, gross	$ 0	$ 20,000

Note 10 - Convertible Notes P_5

Note 10 - Convertible Notes Payable - Related Parties - Convertible Notes Payable to Related Parties (Details) (Parentheticals) - Convertible Debt Payable to Related Party [Member]	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Bill Chaaban, President of Cen Biotech [Member]
Interest Rate		12.00%
Conversion Rights		867,576
Maturity date		Aug. 17, 2020
Director, Harold Aubrey de Lavenu [Member]
Interest Rate	5.00%	5.00%
Conversion Rights	548,980	548,980
Maturity date	Mar. 31, 2019	Mar. 31, 2019
Joseph Byrne [Member]
Interest Rate	12.00%	12.00%
Conversion Rights	76,123	76,123
Maturity date	Aug. 17, 2020	Aug. 17, 2020
Jeff Thomas [Member]
Interest Rate	5.00%	5.00%
Conversion Rights	94,488	94,488
Maturity date	May 24, 2022	May 24, 2022
Director, Alex Tarrabain [Member]
Interest Rate		5.00%
Conversion Rights		30,000
Brother of Director Ameen Ferris [Member]
Interest Rate		5.00%
Conversion Rights		12,500

Note 11 - CEBA Loan Payable (De

Note 11 - CEBA Loan Payable (Details Textual)	Dec. 31, 2022	Sep. 30, 2021USD ($)	Sep. 30, 2021CAD ($)	Dec. 31, 2020USD ($)
Loans Payable, Noncurrent, Total		$ 31,396		$ 0
Canada Emergency Business Account Loan Payable [Member] | Unsecured Debt [Member] | Royal Bank of Canada [Member]
Loans Payable, Noncurrent, Total		$ 31,396	$ 40,000
Canada Emergency Business Account Loan Payable [Member] | Unsecured Debt [Member] | Royal Bank of Canada [Member] | Forecast [Member]
Debt Instrument, Interest Rate, Stated Percentage	5.00%

Note 12 - Governmental Assist_2

Note 12 - Governmental Assistance (Details Textual) - USD ($)	3 Months Ended	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2021
Clear Com Media, Inc [Member]
Proceeds from Governmental Assistance	$ 116,610	$ 116,610

Note 13 - Leases (Details Textu

Note 13 - Leases (Details Textual)	Aug. 01, 2020USD ($)	Oct. 01, 2017CAD ($)	Sep. 30, 2022CAD ($)	Sep. 30, 2021USD ($)	Sep. 30, 2020USD ($)	Sep. 30, 2021USD ($)	Sep. 30, 2021CAD ($)	Sep. 30, 2020USD ($)	Dec. 31, 2020USD ($)
Operating Lease, Impairment Loss				$ 0	$ 146,795	$ 0		$ 146,795
Operating Lease, Liability, Total				318,775		318,775
Leases Office Space from R&D Labs Canada, Inc [Member]
Operating Lease, Monthly Rent		$ 2,608
Operating Lease, Impairment Loss	$ 146,795
Operating Lease, Liability, Total				$ 318,775		$ 318,775			$ 164,997
Operating Lease, Weighted Average Discount Rate, Percent				6.70%		6.70%			6.70%
Operating Lease, Weighted Average Remaining Lease Term (Year)				4 years 7 months 6 days		4 years 7 months 6 days			4 years 7 months 6 days
Operating Lease, Expense					2,982			20,391
Leases Office Space from R&D Labs Canada, Inc [Member] | General and Administrative Expense [Member]
Operating Lease, Expense				$ 17,594	$ 5,248	$ 28,343		$ 18,501
Leases Office Space from R&D Labs Canada, Inc [Member] | Forecast [Member]
Operating Lease, Monthly Rent			$ 3,390
Minimum [Member]
Operating Lease, Monthly Rent							$ 844
Maximum [Member]
Operating Lease, Monthly Rent							$ 5,595

Note 13 - Leases - Future Minim

Note 13 - Leases - Future Minimum Operating Lease Payments (Details)	Sep. 30, 2021USD ($)
2022	$ 110,969
2023	89,879
2024	75,522
2025	31,930
2026	31,930
Thereafter	31,930
Total lease payments	372,159
Less imputed interest	53,384
Present value of lease liability	$ 318,775

Note 14 - Income Taxes (Details

Note 14 - Income Taxes (Details Textual) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Operating Loss Carryforwards, Total	$ 29,200,000		$ 29,200,000
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount	$ 100,000	$ 700,000	$ 4,300,000	$ 1,400,000

Note 14 - Income Taxes - Reconc

Note 14 - Income Taxes - Reconciliation of Effective Tax Rate (Details)	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Income tax benefit at Canadian statutory rate	26.50%	26.50%
Valuation allowance	(26.50%)	(26.50%)
Effective income tax rate	0.00%	0.00%

Note 14 - Income Taxes - Deferr

Note 14 - Income Taxes - Deferred Tax Assets (Details) - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Deferred tax asset - net operating losses	$ 7,700,000	$ 3,400,000
Deferred tax asset valuation allowance	(7,700,000)	(3,400,000)
Net deferred tax asset	$ 0	$ 0

Note 15 - Shareholders' Defic_2

Note 15 - Shareholders' Deficit / Stock Activity (Details Textual) - $ / shares $ / shares in Thousands	Sep. 30, 2021	Dec. 31, 2020
Common Stock, No Par Value (in dollars per share)	$ 0	$ 0
Common Stock, Capital Shares Reserved for Future Issuance (in shares)	1,271,406

Note 16 - Related Party Trans_2

Note 16 - Related Party Transactions (Details Textual)	Aug. 01, 2020USD ($)shares	Oct. 01, 2017CAD ($)	Jan. 31, 2017CAD ($)	Sep. 30, 2021USD ($)	Sep. 30, 2020USD ($)	Sep. 30, 2021USD ($)	Sep. 30, 2020USD ($)	Dec. 31, 2017USD ($)	Dec. 31, 2020USD ($)	Dec. 14, 2017	Dec. 02, 2017	Jul. 12, 2017
Notes Receivable, Related Parties, Current				$ 0		$ 0			$ 17,901
Stock Issued During Period, Value, Issued for Settlement of Lease Termination					$ 50,700		$ 50,700
Operating Lease, Right-of-Use Asset				150,323		150,323			0
Operating Lease, Liability, Total				318,775		318,775
Gain (Loss) on Termination of Lease						0	(2,992)
Lease Arrangement, 20 North Rear Road [Member]
Operating Lease, Monthly Rent			$ 4,000
Lessee, Operating Lease, Term of Contract (Year)			5 years
Stock Issued During Period, Shares, Issued for Settlement of Lease Termination (in shares) | shares	36,500
Stock Issued During Period, Value, Issued for Settlement of Lease Termination	$ 50,700
Lessee, Operating Lease, Discount Rate	8.00%
Operating Lease, Right-of-Use Asset	$ 48,110
Operating Lease, Liability, Total	45,118
Gain (Loss) on Termination of Lease	$ (53,692)
Leases Office Space from R&D Labs Canada, Inc [Member]
Operating Lease, Monthly Rent		$ 2,608
Operating Lease, Liability, Total				$ 318,775		$ 318,775			164,997
Operating Lease, Expense					2,982		20,391
Long-term Convertible Notes Payable to Multiple Private Investors [Member]
Debt Instrument, Interest Rate, Stated Percentage												5.00%
CEN Biotech Ukraine [Member] | XN Pharma [Member]
Ownership Percentage										49.00%
CEN Biotech Ukraine [Member]
Percentage of Related Party's Equity Interest Owned by Director										25.50%
Business Acquisition, Percentage of Voting Interests Acquired										51.00%
Emergence Global [Member]
Notes Receivable, Related Parties, Current									17,901
Joseph Byrne [Member]
Percentage of Related Party's Equity Interest Owned				5.00%		5.00%
CEN Biotech Ukraine [Member]
Notes Receivable, Related Parties, Current									17,901
Due from Related Parties, Total				$ 1,299,328		$ 1,299,328			1,179,328
Percentage of Related Party's Equity Interest Owned by Director											51.00%
CEN Biotech Ukraine [Member] | Equipment Sold to Related Party in Exchange for Note Receivable [Member]
Adjustments to Additional Paid in Capital, Dividends in Excess of Retained Earnings								$ 255,141
Notes Receivable, Related Parties								44,859
Board Members and Officers [Member] | Consulting Fees [Member]
Related Party Transaction, Amounts of Transaction				53,914	$ 31,200	131,914	$ 93,600
Due to Related Parties, Total				$ 462,114		$ 462,114			$ 330,200
R&D Labs Canada, Inc [Member] | Purchased Equipment in Exchange for Note Payable [Member]
Notes Payable, Related Parties								$ 300,000

Note 17 - Stock Based Compens_3

Note 17 - Stock Based Compensation (Details Textual) - USD ($)	Jul. 13, 2021	Jun. 25, 2021	Apr. 02, 2021	Sep. 25, 2020	Aug. 27, 2020	Apr. 17, 2020	Apr. 02, 2020	Oct. 01, 2019	May 16, 2019	Nov. 30, 2017	Sep. 30, 2021	Jun. 25, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020	Nov. 29, 2017
Common Stock, Capital Shares Reserved for Future Issuance (in shares)											1,271,406			1,271,406
Stock Issued During Period, Shares, Issued for Services (in shares)	500,000			162,500	162,500	225,000		50,000
Stock Issued During Period, Value, Issued for Services						$ 162,000					$ 275,000		$ 117,000	$ 1,172,000	$ 279,000
President [Member]
Employment Agreement, Base Annual Salary										$ 31,200
Employment Agreement, Compensation, Shares of Restricted Stock (in shares)										8,750,000
President [Member] | Vested Immediately [Member]
Employment Agreement, Compensation, Shares of Restricted Stock (in shares)										7,400,000
Chief Executive Officer [Member]
Employment Agreement, Base Annual Salary										$ 31,200
Employment Agreement, Compensation, Shares of Restricted Stock (in shares)										1,250,000
Accrued Salaries							$ 58,500
Number of Restricted Shares to settle Accrued Salaries (in shares)							337,500
Chief Executive Officer [Member] | Vested Immediately [Member]
Employment Agreement, Compensation, Shares of Restricted Stock (in shares)										325,000
Senior Executive Vice President and Chief Financial Officer [Member]
Employment Agreement, Base Annual Salary										$ 31,200
Employment Agreement, Compensation, Shares of Restricted Stock (in shares)										4,500,000
Senior Executive Vice President and Chief Financial Officer [Member] | Vested Immediately [Member]
Employment Agreement, Compensation, Shares of Restricted Stock (in shares)										4,140,000
Vice President [Member]
Employment Agreement, Base Annual Salary										$ 31,200
Employment Agreement, Compensation, Shares of Restricted Stock (in shares)										750,000
Vice President [Member] | Vested Immediately [Member]
Employment Agreement, Compensation, Shares of Restricted Stock (in shares)										300,000
Chief Financial Officer [Member]
Employment Agreement, Base Annual Salary									$ 31,200
Employment Agreement, Compensation, Shares of Restricted Stock (in shares)									1,250,000
Chief Financial Officer [Member] | Vested Immediately [Member]
Employment Agreement, Compensation, Shares of Restricted Stock (in shares)									350,000
Director, Harold Aubrey de Lavenu [Member]
Annual Salary			$ 31,200
Restricted Shares Issued for Security Consulting Services [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)										1,870,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period (in shares)										1,330,000
Restricted Shares Issued for Security Consulting Services [Member] | Director,Donald Strilchuck [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)										1,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period (in shares)										550,000
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)											500,000		162,500	12,559,291	387,500
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period (in shares)											575,000		500,000	12,784,291	1,737,500
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Grant Date Fair Value	$ 275,000				$ 117,000						$ 275,000		$ 117,000	$ 16,021,822	$ 279,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grant Date Fair Value														$ 29,035,063		$ 13,013,241
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)														3 years
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value											350,750		355,500	$ 16,249,072	1,053,000
Share-based Payment Arrangement, Expense											75,750		196,650	15,077,072	589,950
Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount											202,000			202,000
Restricted Stock [Member] | Consulting Fees [Member]
Share-based Payment Arrangement, Expense											$ 275,000		$ 117,000	$ 1,172,000	$ 279,000
Restricted Stock [Member] | CONFIEN SAS [Member]
Stock Issued During Period, Shares, Issued for Services (in shares)			650,000
Stock Issued During Period, Value, Issued for Services			$ 897,000
Restricted Stock [Member] | Director, Harold Aubrey de Lavenu [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)			1,041,250
Restricted Stock [Member] | Director, Ameen Ferris [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)			1,000,000
Restricted Stock [Member] | Directors Ameen Ferris and Harold Aubrey De Lavenu [Member]
Stock Issued During Period, Value, Issued for Services			$ 2,816,925
Restricted Stock [Member] | Richard Boswell [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)			2,185,679
Stock Issued During Period, Value, Issued for Services			$ 3,016,237
Restricted Stock [Member] | Bahige Chaaban [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)			3,106,122
Stock Issued During Period, Value, Issued for Services			$ 4,286,435
Restricted Stock [Member] | Brian Payne [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)			1,435,000
Stock Issued During Period, Value, Issued for Services			$ 1,980,300
Restricted Stock [Member] | Usamakh Saadikh [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)			1,000,000
Stock Issued During Period, Value, Issued for Services			$ 1,380,000
Restricted Stock [Member] | Donald Strilchuck [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)			341,250
Stock Issued During Period, Value, Issued for Services			$ 470,925
Restricted Stock [Member] | Director, Alex Tarrabain [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)		1,000,000	300,000
Stock Issued During Period, Value, Issued for Services												$ 899,000
2017 Equity Compensation Plan [Member]
Common Stock, Capital Shares Reserved for Future Issuance (in shares)																	20,000,000
The 2021 Equity Compensation Plan [Member]
Common Stock, Capital Shares Reserved for Future Issuance (in shares)			20,000,000

Note 17 - Stock Based Compens_4

Note 17 - Stock Based Compensation - Restricted Stock Award Activity (Details) - Restricted Stock [Member] - $ / shares	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020	Dec. 31, 2019
Non-vested, number of share (in shares)			425,000	2,025,000	2,025,000
Non-vested, weighted average grant date fair value (in dollars per share)			$ 1.01	$ 0.76	$ 0.76
Non-vested, weighted average remaining contractual term (Year)			9 months	1 year 4 months 9 days	1 year 6 months	1 year 6 months 14 days
Granted, number of share (in shares)	500,000	162,500	12,559,291	387,500
Granted, weighted average grant date fair value (in dollars per share)			$ 1.28	$ 0.72
Vested, number of share (in shares)	(575,000)	(500,000)	(12,784,291)	(1,737,500)
Vested, weighted average grant date fair value (in dollars per share)			$ 1.27	$ 0.71
Forfeited, number of share (in shares)			0	0
Forfeited, weighted average grant date fair value (in dollars per share)			$ 0	$ 0
Non-vested, number of share (in shares)	200,000	675,000	200,000	675,000	425,000	2,025,000
Non-vested, weighted average grant date fair value (in dollars per share)	$ 1.01	$ 0.91	$ 1.01	$ 0.91	$ 1.01	$ 0.76

Note 18 - Net Loss Per Share -

Note 18 - Net Loss Per Share - Antidilutive Securities (Details) - shares	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Convertible Debt Securities [Member]
Antidilutive Securities (in shares)	1,271,406	5,733,735	1,163,866	5,425,999

Note 20 - Fair Value Disclosu_3

Note 20 - Fair Value Disclosures - Fair Value of Financial Instruments (Details) - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Reported Value Measurement [Member]
Cash and cash equivalents	$ 213,805	$ 1,908
Note receivable – CEN Biotech Ukraine, LLC – related party	44,859	44,859
Loans payable	1,986,670	527,379
Loans payable – related parties	2,701,452	1,363,354
Patent acquisition liability	354,900	1,380,000
Convertible notes payable	749,526	6,730,448
Convertible notes payable – related parties	1,036,434	2,558,681
Other receivables		113,999
Reported Value Measurement [Member] | CEBA, Loan Payable [Member]
Loans payable	31,396
Reported Value Measurement [Member] | CEN Biotech Ukraine [Member]
Advances to Subsidiary	1,299,328	1,179,328
Reported Value Measurement [Member] | Emergence Global [Member]
Advances to Subsidiary		17,901
Estimate of Fair Value Measurement [Member]
Cash and cash equivalents	213,805	1,908
Note receivable – CEN Biotech Ukraine, LLC – related party	44,859	44,859
Loans payable	1,986,670	527,379
Loans payable – related parties	0	0
Patent acquisition liability	354,900	1,380,000
Convertible notes payable	1,962,985	7,766,663
Convertible notes payable – related parties	0	0
Other receivables		113,999
Estimate of Fair Value Measurement [Member] | CEBA, Loan Payable [Member]
Loans payable	31,396
Estimate of Fair Value Measurement [Member] | CEN Biotech Ukraine [Member]
Advances to Subsidiary	1,299,328	1,179,328
Estimate of Fair Value Measurement [Member] | Emergence Global [Member]
Advances to Subsidiary		17,901
Estimate of Fair Value Measurement [Member] | Fair Value, Inputs, Level 1 [Member]
Cash and cash equivalents	0	0
Note receivable – CEN Biotech Ukraine, LLC – related party	0	0
Loans payable	0	0
Loans payable – related parties	0	0
Patent acquisition liability	354,900	0
Convertible notes payable	0	0
Convertible notes payable – related parties	0	0
Other receivables		0
Estimate of Fair Value Measurement [Member] | Fair Value, Inputs, Level 1 [Member] | CEBA, Loan Payable [Member]
Loans payable	0
Estimate of Fair Value Measurement [Member] | Fair Value, Inputs, Level 1 [Member] | CEN Biotech Ukraine [Member]
Advances to Subsidiary	0	0
Estimate of Fair Value Measurement [Member] | Fair Value, Inputs, Level 1 [Member] | Emergence Global [Member]
Advances to Subsidiary		0
Estimate of Fair Value Measurement [Member] | Fair Value, Inputs, Level 2 [Member]
Cash and cash equivalents	213,805	1,908
Note receivable – CEN Biotech Ukraine, LLC – related party	0	0
Loans payable	0	0
Loans payable – related parties	0	0
Patent acquisition liability	0	0
Convertible notes payable	0	0
Convertible notes payable – related parties	0	0
Other receivables		0
Estimate of Fair Value Measurement [Member] | Fair Value, Inputs, Level 2 [Member] | CEBA, Loan Payable [Member]
Loans payable	0
Estimate of Fair Value Measurement [Member] | Fair Value, Inputs, Level 2 [Member] | CEN Biotech Ukraine [Member]
Advances to Subsidiary	0	0
Estimate of Fair Value Measurement [Member] | Fair Value, Inputs, Level 2 [Member] | Emergence Global [Member]
Advances to Subsidiary		0
Estimate of Fair Value Measurement [Member] | Fair Value, Inputs, Level 3 [Member]
Cash and cash equivalents	0	0
Note receivable – CEN Biotech Ukraine, LLC – related party	44,859	44,859
Loans payable	1,986,670	527,379
Loans payable – related parties	0	0
Patent acquisition liability	0	1,380,000
Convertible notes payable	1,962,985	7,766,663
Convertible notes payable – related parties	0	0
Other receivables		113,999
Estimate of Fair Value Measurement [Member] | Fair Value, Inputs, Level 3 [Member] | CEBA, Loan Payable [Member]
Loans payable	31,396
Estimate of Fair Value Measurement [Member] | Fair Value, Inputs, Level 3 [Member] | CEN Biotech Ukraine [Member]
Advances to Subsidiary	$ 1,299,328	1,179,328
Estimate of Fair Value Measurement [Member] | Fair Value, Inputs, Level 3 [Member] | Emergence Global [Member]
Advances to Subsidiary		$ 17,901

Note 21 - Segment Information_2

Note 21 - Segment Information (Details Textual)	9 Months Ended
	Sep. 30, 2021
Number of Reportable Segments	2

Note 21 - Segment Information -

Note 21 - Segment Information - Segment Information (Details) - USD ($)	3 Months Ended		9 Months Ended		64 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Jul. 08, 2021
Revenue	$ 272,166	$ 0	$ 272,166	$ 0	$ 0
Operating loss	(644,976)	(968,424)	(17,253,393)	(2,189,621)
Depreciation expense	10,968	1,532	10,968	10,724
Interest income	87	1,553	481	5,465
Interest expense	71,567	813,984	365,170	2,409,129
Capital expenditures			18,988	0
Growth [Member]
Revenue	0	0	0	0
Operating loss	(570,311)	(968,424)	(17,178,728)	(2,189,621)
Depreciation expense	0	1,532	0	10,724
Amortization expense	106,203	106,203	318,609	318,609
Interest income	0	1,553	394	5,465
Interest expense	173,412	921,017	703,665	2,727,672
Capital expenditures	0	0	0	0
Digital [Member]
Revenue	272,166	0	272,166	0
Operating loss	(74,665)	0	(74,665)	0
Depreciation expense	10,968	0	10,968	0
Amortization expense	24,350	0	24,350	0
Interest income	87	0	87	0
Interest expense	0	0	0	0
Capital expenditures	$ 18,988	$ 0	$ 18,988	$ 0

Note 21 - Segment Information_3

Note 21 - Segment Information - Segment Assets to Total Assets (Details) - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Total assets	$ 8,401,965	$ 6,314,142
Growth [Member]
Total assets	5,989,211	6,314,142
Digital [Member]
Total assets	$ 2,412,754	$ 0

Note 22 - Subsequent Events (De

Note 22 - Subsequent Events (Details Textual)	Nov. 19, 2021	Nov. 19, 2021USD ($)	Sep. 30, 2021USD ($)	Sep. 30, 2020USD ($)
Proceeds from Convertible Debt			$ 412,830	$ 499,000
Convertible Debt [Member]
Debt Instrument, Convertible, Number of Equity Instruments			551,815
Subsequent Event [Member] | Convertible Debt [Member]
Proceeds from Convertible Debt		$ 100,000
Debt Instrument, Convertible, Number of Equity Instruments	457,517	416,667